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Preface 
In 1995, the municipal medical officer in Sandnes, Hans Petter Torvik, asked me to 
represent the local health authorities in the advisory board of a research project. The 
project, called “Legal drugs gone astray”, was conducted at the International Research 
Institute of Stavanger, and investigated the black market and the illegal distribution of 
legally prescribed drugs in our municipality. Through the work of the committee, my 
interest in research grew, and after one year I left the committee and joined the 
research team, as part-time employee at the institute.  
Due to my wife’s work, our family moved to Madagascar in 2001. Returning back 
after a two-year stay in a developing country, I perceived the daily life in Norway and 
my work at a primary health care center with a different mind.  
This thesis was inspired by my first project, my renewed experience of the Norwegian 
culture, and the day to day work as a GP in the primary health care system. 
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Abstract 
Background  
One out of three persons in Norway had a mental illness during 2008, and about half 
of the population will be affected during their lifetime, according to the Government. 
Although mental health care comprises many other aspects than pharmacotherapy, 
drugs are widely used to treat psychiatric problems. In this project, the current use of 
psychotropic drugs in various parts of the health care system is analyzed. No detailed 
scientific information exists about the relative contribution from different physician 
groups as regards the prescribing of psychotropic drugs. 
Aims 
The main aims of this study were to examine prevalence rates, incidence rates and 
distribution of psychotropic drug use, i.e. antipsychotics, antidepressants, anxiolytics 
and hypnotics, with special emphasis on the pattern of prescribing in primary and 
secondary health care.  
Material and methods 
Data on all prescriptions of psychotropic drugs dispensed from all Norwegian 
pharmacies from 1 January 2004 until 31 August 2009 were extracted from the 
Norwegian Prescription Database and merged with data about all general practitioners 
(GPs) in Norway in the same period from the General Practitioner Database, and 
information about the general Norwegian population from Statistics Norway. 
Prevalence rates were based on all redeemed prescriptions of these drugs in 2005, 
while new users of antipsychotics and antidepressants in 2008 or of anxiolytics and 
hypnotics in 2005 were used to calculate incidence rates. The course of the treatment 
with anxiolytics and hypnotics was analyzed using a 3.5-year period of follow-up. 
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Results  
The prevalence rates per 1,000 inhabitants were 153 for any psychotropic drug, or  
24 for antipsychotics, 60 for antidepressants, 62 for anxiolytics and 79 for hypnotics 
(Paper I). The incidence rates were 3.4 for antipsychotics and 8.6 for antidepressants 
(Paper II), and 18.2 for anxiolytics, 24.5 for hypnotics, or 35.4 per 1,000 for 
anxiolytics and hypnotics combined (Paper III). Both prevalence rates and incidence 
rates were higher for women than men, and increased by age.  
Psychiatrists prescribed an important part of drug treatment to children and 
adolescents. GPs prescribed the vast majority, but also initiated psychotropic drug 
treatment to most patients, and the proportion increased by patients’ age. The average 
treatment duration declined with increased age of the patients in all four drug classes. 
The duration was longest for hypnotics and anxiolytics, and only every third patient 
received short-term treatment, as recommended. The total drug volume of anxiolytics 
and hypnotics redeemed during the first quarter emerged as the strongest predictor of 
both long-term and heavy use of such drugs.  
Conclusions 
Prevalence and incidence rates for psychotropic drug use in Norway are among the 
highest in Europe. GPs initiate and maintain the drug treatment to the majority. Hence, 
the quality of psychotropic drug treatment is mainly dependent on the knowledge and 
practice of each GP. Psychiatrists contribute mainly among children and adolescents 
and their share of prescriptions decreased significantly with increasing patient age. An 
increased focus from psychiatrists towards the increasingly ageing part of the 
population seems requisite.  
The study confirms that GPs have a key function in the Norwegian health care system, 
also when it comes to treatment of mental disorders. Improving mental health care is 
only achieved in a cost effective manner if GPs are a major part of the effort. 
Implementation of relevant guidelines and systems for structured clinical audit are 
recommended, especially in general practice.  
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Sammendrag på norsk (Norwegian summary)  
Bakgrunn  
En av tre personer hadde en psykisk lidelse i Norge i 2008, og omkring halvparten vil 
bli rammet av en slik lidelse i løpet av livet, i følge regjeringen. Selv om psykisk 
helsetjeneste omfatter mye mer enn medikamentell behandling, er psykofarmaka mye 
brukt i behandling av psykiske lidelser. I dette prosjektet analyseres dagens bruk av 
psykofarmaka i ulike deler av helsetjenesten. Det finnes i dag ingen detaljert 
vitenskapelig informasjon om det relative bidraget fra ulike legegrupper når det gjelder 
forskrivningen av psykofarmaka.  
Studiens formål  
Hovedmålene for denne studien var å analysere omfanget av psykofarmaka 
forskrivning (prevalens), dvs. antipsykotika, antidepressiva, beroligende og 
sovemedisiner, antall nye brukere (insidens), med spesiell vekt på fordelingen av 
forskrivningen av slike legemidler i første og andrelinjetjenesten.  
Materiale og metode  
Data fra Reseptregisteret vedrørende alle resepter på psykofarmaka innløst ved norske 
apotek fra 1. januar 2004 til 31. august 2009 ble koblet sammen med informasjon fra 
Fastlegedatabasen om alle fastleger i perioden, og data vedrørende den generelle 
befolkning fra Statistisk sentralbyrå.  
Analysen av prevalensrater baserte seg på resepter innløst i 2005, mens nye brukere av 
antipsykotika og antidepressiva i 2008 og av beroligende og sovemedisiner i 2005 ble 
brukt til å beregne insidensrater. Forløpet av behandlingen med beroligende og 
sovemedisiner ble analysert over en periode på 3,5 år.  
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Resultat 
Prevalensraten per 1000 innbyggere var 153 for psykofarmaka samlet, og 24 for 
antipsykotika, 60 for antidepressiva, 62 for beroligende og 79 for sovemedisin  
(Paper I). Insidensratene per 1000 innbyggere var 3,4 for antipsykotika, 8,6 for 
antidepressiva (Paper II), 18,2 for beroligende, 24,5 for sovemedisiner eller 35,4 om 
beroligende og sovemedisiner beregnes samlet (Paper III). Andelen som begynte med 
eller brukte slike legemidler økte med alderen, og var høyere for kvinner enn for 
menn.  
Psykiaternes forskrivning utgjorde en betydelig andel av psykofarmakabehandlingen 
til barn og unge. Fastlegene både startet behandlingen og skrev ut resepter til videre 
behandling til de fleste pasientene, og andelen økte med pasientenes alder.  
Gjennomsnittlig behandlingstid ble redusert ved økende pasientalder for alle de fire 
legemiddelgruppene. Varigheten var lengst for sovemedisiner og beroligende, og kun 
en tredjedel av pasientene fikk korttidsbehandling slik retningslinjene anbefaler. 
Totalvolumet pasienten mottok i første behandlingskvartal var den sterkeste prediktor 
for utvikling av langtidsbruk eller storforbruk av beroligende eller sovemedisiner.  
Konklusjon  
Prevalens- og insidensratene for psykofarmaka i Norge er blant de høyeste i Europa. 
Fastlegene både starter og vedlikeholder behandlingen til de fleste. Kvaliteten på 
psykofarmaka behandlingen er derfor i hovedsak avhengig av den enkelte fastlege sin 
kunnskap og praksis. Psykiaterne bidrar i hovedsak blant barn og unge, og deres andel 
av reseptene reduseres raskt med økende pasientalder. Et økt engasjement fra 
psykiatere overfor den stadig mer aldrende del av befolkningen synes nødvendig.  
Studien bekrefter at fastlegene har en nøkkelfunksjon i norsk helsevesen, også når det 
gjelder psykiske lidelser. Et bedre psykisk helsevern kan bare oppnås på en 
kostnadseffektiv måte hvis fastlegene er en viktig del av satsningen. Implementering 
av relevante retningslinjer og systemer for strukturert kvalitetsforbedring anbefales, 
spesielt i allmennpraksis.  
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Abbrevations 
ATC Anatomical Therapeutic Chemical classification system 
BZD(s) Benzodiazepine(s) 
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GP(s) General practitioner(s) 
ICD The International Statistical Classification of Diseases and 
Related Health Problems 
ICPC The International Classification of Primary Care 
NorPD The Norwegian Prescription Database 
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OTC  Over-The-Counter, i.e. without prescription   
SD Standard deviation  
SSRI Selective serotonin re-uptake inhibitor 
TCA Tricyclic antidepressant 
UK United Kingdom  
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WHO World Health Organization 
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Z-hypnotic(s) Benzodiazepine related hypnotic(s) 
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1. Introduction 
Mental health is crucial to the well-being of individuals, societies and countries. 
Physical health affects mental health, and mental health inherently affects physical 
health (1-2).  
1.1 Mental health 
The World Health Report in 2001 (1) stated that globally, one out of four persons will 
be affected by a psychiatric disorder at some stage of life. Major depression was 
ranked as the leading course of years of life lived with disabilities, with schizophrenia 
and bipolar affective disorder as number seven and nine, respectively. Depression was 
number four of leading causes of global burden of disease in 2001, measured by the 
disability-adjusted life years, but anticipated to be number two in 2020. Anxiety and 
insomnia are among the most prevalent psychological symptoms, ranging from mild 
disturbances to severe disorders, and often as comorbidity in other psychiatric 
disorders (3-4). Only a minority of the many millions of people with mental disorders 
receives treatment, and unnecessary suffering, stigmatization and discrimination are 
often the result. Thus, mental health problems are among the main challenges for 
health care systems worldwide. 
To improve the situation, the World Health Report 2001 recommended ten actions to 
be adapted by every country, according to their needs and resources;  
1. Provide treatment in primary care  
2. Make psychotropic drugs available  
3. Give care in the community  
4. Educate the public  
5. Involve communities, families and 
consumers 
6. Establish national policies, 
programs and legislation 
7. Develop human resources 
8. Link with other sectors 
9. Monitor community mental health 
10. Support more research 
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The first, second and sixth recommendation are of particular interest to this project. 
According to the report, management and treatment of mental health in primary care 
enables the largest number of patients to get help, and cuts wastage from unnecessary 
investigation and inappropriate and non-specific treatments at higher health care 
levels. The WHO list of essential drugs (5) includes psychotropic drugs which should 
be provided in all countries, and made constantly available at all health care levels. 
Drugs recommended as the most appropriate treatment for various disorders should be 
made available whenever possible. National policies, programs and legislations are of 
similar importance to secure sustained actions, reduce burden of mental disease, and 
counteract discrimination against persons with mental disorders.  
Patients referred from a GP to a specialist represent a selection of the general 
population, and the probability of disease is higher in this sample than among patients 
in primary care. Consequently, symptoms, signs and test results among referred 
patients have a higher predictive value than in general practice (6). Psychological 
problems are more likely to be caused by a mental disorder in a patient who consults a 
psychiatrist, while similar symptoms in primary care may be only a nuisance. As an 
example, the probability that insomnia may be a symptom of mania is much higher in 
a patient at the psychiatric outpatient clinic than at the GP’s office. 
These differences are reflected by the distinctions between diagnostic classification 
systems. In Norway, The International Classification of Primary Care (ICPC) was 
introduced in family medicine in 1992 (7). ICPC covers symptoms, ailments and 
functional ability as well as diagnoses. This is suitable in primary care, where all kinds 
of health phenomena, problems and disorders may be on patients’ agenda. The 
diagnostic classification system in specialist health care is more focused on diseases, 
their subtypes and severity. Two systems are in use in specialized mental health care, 
The International Statistical Classification of Diseases and Related Health Problems 
(ICD) and The Diagnostic and Statistical Manual of Mental Disorders (DSM). The 
current version, ICD-10, is the main system in Norway, and considered most suitable 
for clinical use, but DSM (current version IV) is valued in research (8).  
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1.2 The health care system in Norway 
Norway has a strong and well-developed public health service, grounded on a concept 
of equality, and with the provision to reach out to everyone regardless of their 
financial situation, social status, age, gender and ethnicity (9). In 2008, Norway spent 
8.6 % of the Gross Domestic Product on health care, and the government paid 84 % of 
the expenditure. In comparison, figure 1 shows the proportions of expenditure that 
were covered by the public in some countries, based on information from the 
Organization for Economic Co-operation and Development, OECD (10). 
Figure 1  Public and private funding of expenditure on health in 2008 
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As in other Western European countries, the demographic situation in Norway is 
changing, and the proportion of the population aged 60 and older is estimated to 
increase from 20 % in 2006 to 30 % in 2050 (11). Such changes will be a major 
challenge to the society and the health care system. Older people need more health 
care and use more medications than younger ones, both for somatic and mental 
reasons.  
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Mental health is an important public health issue among older people, and treatment 
with psychotropic drugs increases by age (12-15). Dementia increases nearly 
exponentially with age from about 60 years (16). Behavioral and psychological 
symptoms are often prominent problems in dementia, and use of psychotropic drugs, is 
pronounced (17). Mental problems as well as medication may increase the risk of falls 
and other comorbidity. Psychological and social factors are important determinants of 
health outcomes in older patients, such as duration of hospital admission or the risk of 
loss of independent living / admission to a nursing home (16).  
Increased number of senior citizens and people with chronic and complex illnesses 
leaves a smaller proportion employable to pay the public bill in years to come, and the 
ratio of population aged 15 to 64 to the population aged 65 and older will change from 
4 to 2 (11). 
A National Regular General Practitioner Scheme was implemented in Norway in 2001, 
giving all inhabitants the right to choose a GP as their regular doctor (18). The reform 
aimed at improving the quality and availability of health care for all inhabitants, but 
especially for patients with chronic conditions, including mental health problems. The 
scheme is provided by the municipalities, and the local health authorities have the 
responsibility to ensure adequate capacity. The GPs are mainly working in private 
practice, contracted by the health authorities in each municipality, although some are 
employed by the municipality on fixed salary. More than 99 % of the population is 
contracted to a GP (19), and both patients and GPs are mainly satisfied with the reform 
(20-21). GPs provide medical care for a wide range of somatic and mental health 
problems. According to the statistics from the Norwegian Labour and Welfare 
Services, 10 % of consultations in primary care were labeled with a mental diagnostic 
code in 2006, both for men and women (22). For service in secondary care, including 
psychiatric and psychological health care, referral from a GP is mandatory. The 
patients are normally re-allocated to primary health care for further follow-up, when 
necessary diagnostics and treatment at the secondary care level are completed.  
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Specialized mental health services comprise psychiatric hospitals and smaller 
decentralized institutions called district psychiatric centers. Both types of institutions 
usually provide in- and outpatients’ services. Most psychiatrists work in these 
institutions in the public health care system. In addition, some psychiatrists and 
psychologists run private specialist practices, based on a contract with the health 
authorities. Visits to GPs, private specialists or outpatient departments are charged 
with a Governmental regulated user fee, while hospital admission is free.  
Some psychiatrists and psychologists run private practices without a contract with the 
authorities, especially in the larger cities. Such treatment is fully paid for by the 
patients or their employer, and no referral is needed. 
A national plan to strengthen mental health care was initiated by the Government in 
1997 (23). A general political agreement stated that mental health care should be 
prioritized. This was followed-up by a national mental health reform aiming to 
improve the availability, the capacity, and the quality of the mental health care (24).  
The recommendations in the World Health Report 2001 may be perceived as already 
implemented in Norway. Still, the impact of mental health problems in Norway is 
pronounced. The patients’ loss of working capacity and the governmental expenses to 
disability pensions ranks the economical consequence of mental health problems as 
number one of health problems, in Norway. The government assessed that one in 
every three persons had a mental illness or disorder during 2008, and approximately 
one of two will be affected during their lifetime (25). Different professions with 
different qualifications are involved in mental health care, and a number of non-
pharmacological and psychotherapeutic strategies are available to treat and support the 
patients. Psychotropic drugs are, however, widely used. The second recommendation 
from WHO emphasizes the importance by making the most efficient drugs available, 
whenever possible, e.g. in Italy, second generation antipsychotics were not covered by 
the reimbursement system until 2001.  
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1.3 Psychotropic drugs  
Psychotropic drugs are in this thesis defined as antipsychotics, anxiolytics, hypnotics 
and antidepressants. Other drugs may also be used for treatment of psychiatric 
conditions, as for instance psychostimulants, drugs used to treat dementia, and 
anticonvulsants for use in bipolar disorder, but such drugs are beyond the scope of this 
project. 
1.3.1 Brief history  
The introduction of chlorpromazine in psychiatry by Delay et al. in 1952 may be 
perceived as the inauguration of modern clinical psychopharmacology (26). It was a 
pharmacological therapy with a specific indication for treatment of psychosis, and 
became the first approved antipsychotic drug. In 1957, the Swiss psychiatrists Kuhn 
showed that imipramine improved the symptoms of depression (27). Imipramine 
together with similar antidepressant drugs became of similar vital importance for the 
treatment of depression as antipsychotics were for psychosis.  
Drugs used for mental problems prior to 1950 were mostly barbiturates which had 
narrow therapeutic windows with high risk of adverse side effects, overdose, 
respiratory depression and even death. The introduction of diazepam as treatment for 
anxiety in the early 1960s soon made barbiturates obsolete. Other benzodiazepines 
(BZDs) followed and have ever since been widely used as anxiolytics but also as 
hypnotics and anticonvulsants.  
Lithium has a different story (28). It was introduced in psychiatry in the mid-19th 
century, but soon forgotten. In 1949 it was reintroduced, and accomplished by a 
randomized controlled trial for mania in 1954. Maintenance and prophylactic therapy 
to avoid manic and depressive periods in bipolar disorders became evident in the 
1960s, but the use in clinical practice developed slowly, and lithium achieved its 
current status with difficulties.  
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Research in the 1950s and 1960s resulted in better understanding of the central 
nervous system and the function of neurotransmitters, but the drugs brought to the 
market until the 1980s were mainly based on development from already known 
chemical substances. During the 1990s and the first years of this millennium, many 
new drugs were brought to the marked, and the overall use of psychotropic drugs 
increased in most high income countries and in all ages, also in children (29-30).  
Earlier, antipsychotics were mainly used to treat patients with severe mental illness, 
often in a mental health care setting. This practice has changed. The newer atypical or 
second generation antipsychotics are approved for some other conditions than non-
affective psychosis, as with bipolar disorder, but off-label prescribing has also been 
much more common (31), especially for behavioral and psychological symptoms of 
dementia (32). The second generation antipsychotics induces less sedative and 
anticholinergic effects than first generation antipsychotics (33), but all antipsychotics 
may induce serious side effects, and physicians need to balance the potential risks and 
benefits of using them. In Norway, the wholesale of antipsychotics has been rather 
stable, but a shift from first generation to second generation drugs has increased the 
expenses considerably (34). 
The introduction of selective serotonin reuptake inhibitors (SSRIs) and other new 
antidepressants have dramatically increased the use of antidepressants. The number of 
persons treated with antidepressants were nearly doubled in the United States between 
1996 and 2005, and antidepressants became the most commonly prescribed drug class 
in the United States in 2005 (35). The increase has been considerable also in Europe 
and other high-income countries (36). In Norway, the wholesale of antidepressants has 
changed from less than 15 DDD per 1,000 inhabitants per day before 1992 to more 
than 55 DDD per 1,000 inhabitants per day from 2007 and later (34).  
Antidepressants are used with other problems than depression. SSRIs are 
recommended as first-line treatment of panic disorders, but also approved for 
treatment of generalized anxiety disorder, obsessive compulsive disorders and some 
phobias. In addition, studies have shown that SSRIs are effective in premenstrual 
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dysphoric disorder (37). Older antidepressants are often used for non-psychiatric 
indications as musculoskeletal conditions, different pain conditions and for sleep 
disturbances. According to a Canadian study, about one-third of antidepressants are 
prescribed for other reasons than depression (38) high-income countries. 
As regards anxiolytics, BZDs have dominated the market since the 1960s, and still do, 
while the new generation of hypnotics, Z-hypnotics, is now the drug of choice (39). 
The long-term consequences of use of Z-hypnotics are still unknown, but they are 
regarded to be safer than BZD in terms of risk for adverse events (40).  
Other drugs such as the antihistamines hydroxyzine and alimemazine are approved for 
treatment of anxiety and insomnia, respectively, but the use is confined. The newer 
anxiolytics include buspirone and alprazolam. Buspirone is useful in treatment of 
anxiety, particularly for those patients who have not used BZD (41). Alprazolam has 
been shown to be effective in treatment of anxiety, but alprazolam is not recommended 
as first-line therapy. More than other BZDs, alprazolam cause withdrawal and rebound 
effects, and may be abused (42). 
In Norway, the total use of anxiolytics has been rather stable during the last twenty 
years. The use of hypnotics decreased during the early 1990s, but has then increased 
again, year by year since 1995 (34). 
1.3.2  Classification of Drugs  
The need for an internationally accepted classification system for drug consumption 
studies was addressed at a symposium in Oslo in 1969 entitled The Consumption of 
Drugs. Norwegian researchers developed the system known as the Anatomical 
Therapeutic Chemical (ATC) classification system (43) by modifying and extending 
the classification of the European Pharmaceutical Market Research Association.  
In the ATC system, drugs are classified into five different levels, according to the 
organ or system on which they act and their therapeutic, pharmacological and 
chemical properties. The system has 14 anatomical main groups (level 1), each with 
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therapeutic subgroups (level 2), and a pharmacological subgroup (level 3), followed by 
chemical subgroups (level 4) and each chemical substance (level 5) (44).  
Table 1 demonstrates the first three levels in the ATC system for psychotropic drugs 
included in this thesis, while table 2 shows the different psychotropic drugs marketed 
in Norway and approved before 2005 and their full ATC codes.  
Table 1  The first, second and third level in the ATC system for psychotropic 
drugs included in this study  
N   Nervous system 1. level, anatomical main group 
 05   Psycholeptics 2. level, therapeutic subgroup  
  
A 
B 
C   
Antipsychotics 
Anxiolytics 
Hypnotics 
3. level, pharmacological subgroup 
3. level, pharmacological subgroup 
3. level, pharmacological subgroup 
 06   Psychoanaleptics 2. level, therapeutic subgroup  
  A   Antidepressants 3. level, pharmacological subgroup 
 
In addition, a unit called the Defined Daily Dose (DDD) was developed. It is defined 
as the assumed average maintenance dose per day for a drug used for its main 
indication in adults (43). DDD does not necessarily reflect the recommended or 
prescribed daily dose, but is a technical unit for measurement often used in research 
and drug statistics. The WHO Regional Office for Europe recommended the ATC / 
DDD system in 1981, and the WHO Collaborating Center for Drug Statistics 
Methodology was established in Oslo in 1982. The center is now located at the 
Norwegian Institute of Public Health, and responsible for the maintenance and further 
development of the ATC / DDD system (44). In 1996, WHO recognized the ATC / 
DDD system as an international standard for drug utilization studies. 
1.3.3 Authorities and legislation 
Until 1995 drugs had to be approved by national authorities in each and every country 
in Europe. Today the European Medicines Agency (EMA) approves drugs for the 
countries in the European Union and in The European Economic Area as Food and 
Drug Administration (FDA) do in the United States.  
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Table 2  Psychotropic drugs marketed in Norway in 2005-2008 
ATC code  Substance Approved  ATC code  Substance Approved 
Antipsychotics   Antidepressants 
N05A A01 Chlorpromazine 1954  N06A A04 Clomipramine 1970 
N05A A02 Levomepromazine 1960  N06A A06 Trimipramine 1966 
N05A B01 Dixyrazine 1965  N06A A09 Amitriptylin 1961 
N05A B02 Fluphenazine 1964  N06A A10 Nortriptyline 1965 
N05A B03 Perphenazine  1958  N06A A12 Doxepin 1969 
N05A B04 Prochlorperazine  1957  N06A B03 Fluoxetine 1995 
N05A C02 Thioridazine 1960  N06A B04 Citalopram 1995 
N05A D01 Haloperidol 1961  N06A B05 Paroxetine 1993 
N05A E03 Sertindole 1997  N06A B06 Sertraline 1996 
N05A E04 Ziprasidone 2002  N06A B08 Fluvoxamine 1990 
N05A F01 Flupentixol 1966  N06A B10 Escitalopram 2002 
N05A F03 Chlorprothixene 1959  N06A G02 Moclobemide 1990 
N05A F05 Zuclopenthixol  1977  N06A X03 Mianserin 1982 
N05A H02 Clozapine 1990  N06A X11 Mirtazapine 2000 
N05A H03 Olanzapine 1997  N06A X16 Venlafaxine 1996 
N05A H04 Quetiapine 2000  N06A X18 Reboxetine 1999 
N05A L05 Amisulpride 1999  N06A X21 Duloksetin 2004 
N05A N01 Lithium 1970    
N05A X08 Risperidone 1994    
N05A X12 Aripiprazole 2004  Hypnotics 
Anxiolytics  N05C D02 Nitrazepam 1965 
N05B A01 Diazepam 1963  N05C D03 Flunitrazepam 1977 
N05B A04 Oxazepam 1966  N05C D08 Midazolam 1986 
N05B A12 Alprazolam 1994  N05C F01 Zopiclone 1994 
N05B B01 Hydroxyzine 1957  N05C F02 Zolpidem 1996 
N05B E01 Buspirone 1992  N05C M02 Clomethiazole 1968 
 
Norway joined the EMA system in 2000, and hence abandoned the former principle 
that new drugs had to demonstrate an "added value" in relation to already approved 
drugs to gain approval. Thus, the number of drugs marketed in Norway has increased. 
The Norwegian Medicines Agency is the national regulatory authority for new and 
existing medicines and the supply chain in Norway (45). The agency has assigned all 
prescription drugs to three classes; ordinary prescription drugs, such as antipsychotics 
and antidepressants, are placed in class C, and those prescriptions are allowed to be 
reiterated for one year. Drugs that are potentially abused or may be addictive are either 
classified in class B, such as BZDs and Z-hypnotics, or in class A, such as opioids, 
central stimulants and other drugs regarded as narcotics. Class A prescriptions need 
special forms. Due to the potential risk for abuse of drugs in class A and B, 
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prescriptions can only be redeemed once, and prescription forms are kept at the 
pharmacies for 5 years (A) or 1 year (B) to secure the authorities a possibility for 
control or investigation of the handling of such drugs.  
An electronic prescription system is developed. It will be implemented in primary care 
in Norway during 2011-2013. The handling of prescriptions will be changed, but the 
main principle in prescribing legislations will be continued. 
A governmental reimbursement system covers prescriptions of drugs for prolonged or 
chronic treatment, including antipsychotics and antidepressants. Patients normally 
have to pay themselves for short-time treatment and for addictive drugs, including 
anxiolytics and hypnotics. Exceptions exist for some anxiolytics when used to treat 
epilepsy and for anxiolytics and hypnotics used by patients with advanced cancer. 
Physicians with or without a specialty, dentists as well as veterinarians are authorized 
to prescribe psychotropic drugs.  
1.4 Pharmacoepidemiology 
According to the WHO (46), Drug Utilization is defined as the “marketing, 
distribution, prescription, and use of drugs in a society, with special emphasis on the 
resulting medical, social and economic consequences”. Consequently, effects of drug 
utilization at all levels of the health care system are included in the term, and both 
quantitative and qualitative methods are used for drug utilization studies. Quantitative 
studies are used to quantify the current state, trends and the course of drug use over 
time, while qualitative methods are valuable tools to gain knowledge about attitudes, 
beliefs, and preferences among patients, physicians or other health care providers.  
Pharmacoepidemiology emerged at the intersection between epidemiology and clinical 
pharmacology. Clinical pharmacology investigates the effects of drugs in humans, and 
epidemiology studies the distribution and determinants of health-related states and 
events in the population. Pharmacoepidemiology applies the methods from 
epidemiology to study the clinical use of drugs in populations, i.e. studies of the use, 
effects or side effects of drugs in a large number of people (47).  
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The main purpose of pharmacoepidemiological research is to support efficient and 
cost-effective use of medicines in the population and thus improve health outcomes. 
Pharmacoepidemiological studies may use descriptive, analytical as well as 
experimental design. Descriptive studies include case reports, case series, and cohort 
or register analyses without a control group (47). Such studies may reveal age and 
gender specific prevalence or incidence rates, distribution and trends in drug use, 
frequencies of adverse drug reactions etc. They may focus on different levels of the 
health care system or different populations. Descriptive studies are usually unable to 
determine causation, but useful for generating hypotheses for further research.  
Analytical studies have the ability to test specific hypothesis, often by using a control 
group. Typical designs in analytical studies are case-control studies, cohort studies, 
nested case-control studies, and case-crossover analyses (47).  
In experimental studies, the researcher controls the intervention that is given each 
participant, normally to randomly allocate patients among study groups as in 
randomized controlled trials. Randomized clinical trials are the study design with best 
control of bias, as selection bias and confounding, and thereby giving the highest 
evidence of causality (47). 
1.4.1 Sources of information 
The ideal source of information for pharmacoepidemiological studies would be a 
database covering a stable population over a lifetime, with a population large enough 
to discover rare events, including records from both inpatients and outpatients in 
primary and specialized health care, covering both somatic and mental health 
problems, and information about all laboratory and imaging results, prescribed and 
over the counter drugs, and alternative therapies (47). Such a database does not exist, 
but the development of large computerized databases has facilitated the evolvement of 
drug utilization and pharmacoepidemiological studies.  
In Sweden, prescriptions to outpatient have been recorded in the database of the 
county Jämtland and in the small town of Tierp since the early 1970s. The health 
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service databases in Saskatchewan in Canada were established in 1975 (48). It was one 
of the first public databases collecting prescription data at the individual level for the 
entire population of a province, and similar databases are established also in Manitoba, 
Quebec, and British Colombia. In the United States, several individual based 
prescription databases have existed since the 1980s, but most are claim databases 
connected to insurance companies, covering samples not representative for the entire 
population (47).  
The General Practice Research Database in United Kingdom was established in 1987. 
It is a database of anonymised medical records linked with other health care data, 
including information about prescriptions (49). Now the database collects information 
from more than 5 million patients from more than 600 general practices (50).  
Other European countries have established databases as well, some more like the 
claims databases in the United States, as for instance in Germany, and some more 
similar to the Canadian types as the provincial databases in Italy. In the Netherlands, 
the PHARMO institute links hospital data with prescription data based on the patients’ 
birth day, gender and GP code (51). The IA-database in Groningen is also a well-
known research database in pharmacoepidemiology and pharmacoeconomics (52).  
Pharmacoepidemiological research has a long tradition in Scandinavian countries. In 
addition to WHO collaborating center for drug statistics in Oslo, the WHO Global 
Drug Surveillance program is located in Uppsala in Sweden (53). The main aim of the 
latter is to detect potential side effects of drugs as early as possible, based on case 
reports about suspected adverse drug reactions from more than 80 countries.  
Since the 1970s, the Nordic countries have assessed trends in drug use based on 
wholesale information. However, data at the individual person level are essential to 
assess drug exposure of the population, and to make it possible to link information 
from different sources together. During the late 1980s, most pharmacies were 
computerized in the Nordic countries, making automated collection of prescription 
data at the individual level possible.  
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The Pharmacoepidemiological Prescription Database of North Jutland in Aarhus and 
the Odense University Pharmacoepidemiological Database (OPED) were established 
in 1989 and 1990, respectively. The data were based on the unique and permanent 
identification number for each citizen, and made it possible to monitor the medication 
for each person over time, and linking data from different registries together (54). The 
sample comprised by the two databases has been rather stable and is recognized as 
representative for the general population, covering around 18 % of the Danish 
population (54). National prescription database were established in Finland in 1993, in 
Denmark in 1994, in Sweden in 2005 and in Iceland in 2006 (55).  
The Norwegian Prescription Database (NorPD) commenced collection of prescription 
data from all pharmacies in Norway from 1 January 2004. A unique pseudonym 
identification code is made for each patient, based on but different from each person’s 
social security number. Similarly, a pseudonym code is made for each prescriber based 
on the authorization code. The codes relate prescription data to each person and 
prescriber over time, and provide opportunities for linking data from different 
databases for research purposes, while personal anonymity is ensured (56). 
1.4.2 Previous studies  
Of special interest to this thesis are studies revealing prevalence rates, incidence rates 
and distribution of psychotropic drug prescriptions among different prescriber groups. 
Comparisons of different studies are hampered by methodological differences with 
regard to data sources, sampling procedures and time frames, but women use much 
more psychotropic drugs than men, and the use increases with patients’ age (57-59). 
Prevalence rates 
The prevalence rate of overall psychotropic drug use revealed in the referred articles 
ranged from 56 to 192 per 1,000 adults, and from 3.4 to 48.7 per 1,000 children and 
adolescents (table 3). The studies are based on different methods and age groups, and 
psychotropic drugs are defined differently.  
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A Danish study (58) included antidepressants, anxiolytics and hypnotics, but not 
antipsychotics due to few users in the material. Ohayon (59) included all drugs 
regarded as psychotropic by the patients, including some OTC drugs. The European 
Study of the Epidemiology of Mental Disorders (57) and the National Health and 
Nutrition Examination Survey from the United States (60) included antipsychotics, 
antidepressants, anxiolytics, hypnotics, and mood stabilizers, while a Canadian study 
(61) also included psychostimulants. Regarding children, the Italian studies (62-63) 
included antipsychotics, antidepressants and stimulants, while the study from Iceland 
(64) also included anxiolytics and hypnotics. The studies from the United States (30, 
63) covered the same groups as well as anticonvulsants.  
Table 3  Prevalence rates of psychotropic drug use per 1,000 inhabitants in 
different countries and years 
Author Country Year Population Method / Material Rate 
Adults 
Nielsen  
(58) 
Denmark  2000 Representative sample 
of 22,486  
aged 16 or older 
Danish Health and Morbidity 
Survey 2000 
56 
men 39 
women 72 
Ohayon  
(59) 
France, Italy 
Germany, UK 
1993-
1997 
Representative sample 
of 18,679  
aged 15 or older  
Telephone survey 64 
Beck  
(61) 
Canada 2002 Representative sample 
of 36,984  
aged 15 or older 
The Canadian Community 
Health Survey 
Medication the last two days  
72  
men 50 
women 95 
Paulose-
Ram (60) 
USA 1999-
2002 
Representative  sample 
of 12,060  
aged 17 or older 
Detailed in-person home 
interview (National Health 
and Nutrition Examination 
Survey)  
111 
Alonso  
(57) 
Germany, The 
Netherlands, 
Belgium, Italy, 
Spain, France 
2001-
2003 
Representative sample 
of 21,425  
aged 18 or older  
Detailed in-person home 
interview with computer-
assisted techniques 
123 
 Germany    59 
The Netherlands 74 
Belgium 132  
Italy 137 
Spain 156 
France 192 
Children and adolescents 
Clavenna  
(62) 
Italy 2004 1,484,770 
aged 17 or younger 
ARNO, a multiregional 
prescription database 
3.0 
Bonati  
(63) 
Italy 2002 Review of  
15 articles 
MEDLINE and  
EMBASE 
3.4 
USA 2000 35.5 
Olfson  
(30) 
USA 1996 6,490  
aged 18 or younger 
Medical Expenditure Panel 
Survey 
39.0 
Zoega  
(64) 
Iceland  2007 All residents (n not stated) 
aged 17 or younger  
The Medicines Registry on 
prescribed drugs in Iceland 
48.7 
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Studies evaluating the use of antipsychotics revealed prevalence rates ranging from  
3 to 13 per 1,000 adults, and from 0.8 to 10.6 per 1,000 children and adolescents  
(table 4). A trend analysis has documented an increased use of antipsychotics in most 
high-income countries since the early 1990s until more recent years (31). 
Table 4  Prevalence rates of antipsychotic drug use per 1,000 inhabitants in 
different countries and years 
Author  Country Year Population  Method / Material Rate 
Adults 
Ohayon  
(59) 
France, Italy 
Germany, UK 
1993-
1997 
Representative 
sample of 18,679 
aged 15 or older  
Telephone survey 3 
Alonso 
(57) 
Germany, The 
Netherlands, 
Belgium, Italy, 
Spain, France 
2001-
2003 
Representative 
sample of 21,425 
aged 18 or older  
Detailed in-person, computer-
assisted, home interview  
12 
Beck 
(61) 
Canada 2002 Representative 
sample of 36,984 
aged 15 or older 
The Canadian Community 
Health Survey 
Medication the last two days 
5 
Mirandola 
(12) 
Italy 2002 2,640,379 residents,  
Province of Veneto  
Data from prescription 
database of reimbursed 
drugs 
men 6 
women 7 
Percudani 
(65) 
Italy 2001 9,121,714 residents,  
Province of Lombardy 
Data from prescription 
database of reimbursed 
drugs 
9 
men 9 
women 10 
Paulose-
Ram (60) 
USA 1999-
2002 
Representative 
sample of 12,060 
aged 17 or older 
Detailed in-person home 
interview (National Health & 
Nutrition Examination Survey) 
10 
Mortimer 
(66) 
UK 2003 Patients from seven 
GPs, 53,000 
The Eastern Hull Primary 
Care Trust 
10 
Domino 
(67) 
USA 2005 Randomly selected 
annual sample of 
23,000–35,000 
Medical Expenditure Panel 
Survey  
12 
Kaye 
(68) 
UK 2000 Patients from GPs  
1.4-1.7 million 
aged 10 or older 
The General Practice 
Research Database 
12 
men 9 
women 15 
Trifiro 
(69) 
Italy 2002 465,061 patients from 
320 GPs  
Sample from the Health 
Search Database  
13 
 
Children and adolescents 
Rani  
(70) 
UK 2005 789 467 patients 
aged 19 or younger 
The General Practice 
Research Database 
0.8 
Clavenna 
(62) 
Italy 2004 1,484,770 
aged 17 or younger 
ARNO multiregional 
prescription database 
men 0.9 
women 0.5 
Olfson 
(30) 
USA 1996 6,490 children  
aged 18 or younger 
Medical Expenditure Panel 
Survey  
2.0 
Bonati  
(63) 
Italy 2002 Review of  
15 articles 
MEDLINE and  
EMBASE 
0.8 
USA 2000 2.8 
The Netherlands 1999 3.4 
Canada 1999 3.8 
Kalverdijk  
(71) 
The Netherlands 2005 119,612 patients 
aged 19 or younger 
The Inter-Action database 6.8 
Zoega  
(64) 
Iceland  2007 Residents (n not stated) 
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
10.6 
 32 
The prevalence rates for antidepressant drug use ranged from 10 to 101 per 1,000 
adults, (table 5 a) and from 1.1 to 23.7 per 1,000 children and adolescents (table 5 b); 
trend analyses have demonstrated a remarkable increase in the use of antidepressants 
since the introduction of the SSRIs (35-36).  
Table 5a  Prevalence rates of antidepressant drug use per 1,000 inhabitants in 
different countries and years 
Author  Country Year Population  Method / Material Rate 
Adults 
Ohayon  
(59) 
France, Italy 
Germany, UK 
1993-
1997 
Representative 
sample of 18,679 
aged 15 or older  
Telephone survey 10  
Alonso 
(57) 
Germany, The 
Netherlands, 
Belgium, Italy, 
Spain, France 
2001-
2003 
Representative 
sample of 21,425 
aged 18 or older  
Detailed in-person, computer-
assisted, home interview  
37 
Isacsson  
(72) 
Sweden  1996 Representative 
sample, 18,000 
The prescription database of 
the county of Jämtland  
13  
men 11 
women 16 
Meijer  
(73) 
The Netherlands 2001 Representative 
sample, 850,000 
The PHARMO database SSRI 17 
TCA   6 
Olfson  
(74) 
USA 1997 Representative 
sample of 32,636  
Medical Expenditure Panel 
Survey 
23 
Nielsen  
(58) 
Denmark  2000 Representative 
sample of 22,486 
aged 16 or older 
Danish Health and Morbidity 
Survey 2000 
26  
men 18 
women 33 
Rosholm 
(75) 
Denmark 1997 Population of Fünen, 
470,000 
The Odense Pharmaco-
epidemiological Database  
41 
Percudani 
(65) 
Italy 2001 9,1 million residents,  
Province of Lombardy 
Data from prescription 
database of reimbursed drug 
44  
men 29 
women 59 
Beck 
(61) 
Canada 2002 Representative 
sample of 36,984 
aged 15 or older 
The Canadian Community 
Health Survey 
Medication the last two days 
47 
Trifiro 
(76) 
Italy 2003-
2004 
142,346 patients from 
119 GPs  
Data from the Arianna 
database  
60 
Bramness 
(77) 
Norway 2004 The Norwegian 
population  
4.6 million 
The Norwegian prescription 
database  
Men 50 
women 93 
Raymond 
(78) 
Canada 2004 4.1 million residents, 
British Columbia 
The British Columbia 
PharmaNet system 
72 
Poluzzi 
(79) 
Italy 2002 4.6 million residents 
in the province  
The Emilia Romagna 
Regional Health Authority 
Database  
78 
Paulose-
Ram (60) 
USA 1999-
2002 
representative 
sample of 12,060  
aged 17 or older 
Detailed in-person home 
interview (National Health 
and Nutrition Examination 
Survey) 
81 
Exeter 
(80) 
New Zealand  2007 Residents (n not stated) 
aged 15 or older  
Pharmaceutical Management 
Agency of New Zealand  
94 
Olfson  
(35) 
USA 2005 Representative 
sample of 32,320 
aged 6 or older 
Medical Expenditure Panel 
Surveys 
101 
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Table 5b  Prevalence rates of antidepressant drug use per 1,000 inhabitants in 
different countries and years 
Author  Country Year Population  Method / Material Rate 
Children and adolescents 
Zito  
(81) 
Germany 2000 480,680 
aged 19 or younger 
Gmuender ErsatzKasse 1.1 
Denmark  2000 111,452 
aged 19 or younger 
The Odense Pharmaco-
epidemiological Database  
1.8 
The Netherlands 2000 72,570 
aged 19 or younger 
The Inter-Action database 5.4 
USA 2000 125,383 
aged 19 or younger 
The State-Children’s Health 
Insurance program 
16.3 
Bonati  
(63) 
Italy 2002 Review of  
15 articles 
MEDLINE and  
EMBASE 
2.8 
The Netherlands 1999 4.4 
UK 1999 6.0 
USA 2000 15.8 
Canada 1999 16.2 
USA 2002 23.7 
Clavenna  
(62) 
Italy 2004 1.5 million  
aged 17 or younger 
ARNO, multiregional 
prescription database 
men 2.6 
women 2.7 
Olfson  
(30) 
USA 1996 6,490  
aged 18 or younger 
Medical Expenditure Panel 
Survey  
10.0 
Zoega  
(64) 
Iceland  2007 Residents (n not stated) 
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
23.4 
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Studies focusing on anxiolytics and hypnotics combined revealed prevalence rates 
ranging from 29 to 106 per 1,000 (table 6). One study revealed the rates for each drug 
group separately with a mean prevalence rate of 43 per 1,000 for anxiolytics and 15 
per 1,000 for hypnotics in France, Germany, Italy, and UK together.  
A Norwegian study on hypnotic drug use in 2006 showed rates of 48 and 90 per 1,000 
as regards Z-hypnotics and 8 and 10 per 1,000 for BZD hypnotics, for men and women 
respectively.  
Only three studies were found assessing the use of anxiolytics and hypnotics among 
children and adolescents, with prevalence rates from 1.8 to 6.9 per 1,000 (table 6). 
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Table 6  Prevalence rates of anxiolytic and hypnotic drug use per 1,000 
inhabitants in different countries and years 
Author  Country Year Population  Method / Material Rate 
Adults Anxiolytics / Hypnotics combined   
Nielsen  
(58) 
Denmark  2000 22,486  
aged 16 or older 
Danish Health and Morbidity 
Survey 2000 
29 
men   19 
women   39 
Beck 
(61) 
Canada 2002 36,984  
aged 15 or older 
The Canadian Community 
Health Survey 
Medication the last two days 
31 
Paulose-
Ram 
(60) 
USA 1999-
2002 
12,060  
aged 17 or older 
Detailed in-person home 
interview (National Health 
and Nutrition Examination 
Survey) 
38 
Lagnaoui 
(82) 
France 2001 4007 aged 18 or older  National cross-sectional 
telephone survey 
75 
men   52 
women   97 
Magrini 
(14) 
Italy 1992-
1993 
2803 patients  
aged 18 or older  
from 62 GPs  
A questionnaire survey  86 
men   50 
women 118 
Alonso 
(57) 
Germany, the 
Netherlands, 
Belgium, Italy, 
Spain, France 
2001-
2003 
21,425  
aged 18 or older  
Detailed in-person 
computer-assisted home 
interviews 
98 
van Hulten 
(83) 
The Netherlands 1993 13,500 patients  
from 6 GPs 
Data from the local 
pharmacy 
100 
men   69 
women 131 
Isacson 
(84) 
Sweden  1976 Population of Tierp, 
20,000 
Local research database 106 
men   71 
women 144 
 Anxiolytics  
Ohayon 
(59) 
France, Italy 
Germany, UK 
1993-
1997 
Representative  
sample of 18,679  
aged 15 or older  
Telephone survey 43 
UK 1994 6 
Germany 1996 7 
Italy 1997 58 
France 1993 90 
 Hypnotics 
Ohayon 
(59) 
France, Italy 
Germany, UK 
1993-
1997 
Representative sample 
of 18,679  
aged 15 or older 
Telephone survey 15 
Germany 1996 7 
Italy 1997 7 
UK 1994 16 
France 1993 25 
Hausken 
(15) 
Norway 2006 All inhabitants  
4.6 million 
aged 18 to 69 
The Norwegian  
Prescription  
Database 
Z-
hypnotics 
BZD 
hypnotics 
men   48 
women   90 
men     8 
women   10 
Children and adolescents Anxiolytics / Hypnotics combined 
Bonati 
(63) 
USA 2000 Review of  
15 articles 
MEDLINE and  
EMBASE 
2.5 
USA 1996 4.9 
The Netherlands 1999 6.9 
Olfson  
(30) 
USA 1996 6,490 children  
aged 18 or younger 
Medical Expenditure Panel 
Survey 
3.0 
 Anxiolytics 
Zoega  
(64) 
Iceland 2007 All residents (n not stated) 
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
1.8 
 Hypnotics 
Zoega  
(64) 
Iceland 2007 All residents (n not stated) 
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
2.6 
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Incidence rates 
Only a few publications were found that revealed incidence rates of psychotropic drug 
use. For adult users, one study from the United Kingdom (68) and two studies from 
Italy (12, 69) calculated incidence rates for antipsychotics (table 7). Both Italian 
studies evaluated the year 2002, even though the results were quite different. The 
study based on the whole population in a province revealed an incidence rate per 1,000 
inhabitants of 2.6, while the study based on the population in a GP database had 10.9. 
In the study from United Kingdom, the rates were 3.3 for men and 5.0 for women.  
Studies from five different countries revealed incidence rates for antidepressants 
ranging from 4.2 to 30.6 per 1,000 adults. The Italian study (76) with the highest 
incidence rate used a GP based database probably not representative of the general 
population. The other studies were based on representative samples, or the entire 
population. In addition to methodological differences, real differences may explain 
some of the variations between the study results. 
No study was found on incidence rates of anxiolytic drug use in adults.  
A Norwegian study (15) revealed incidence rates for hypnotics of 18.4 and 1.3 per 
1,000 adult men for Z-hypnotics and BZD hypnotics, respectively, and 29.6 and 1.3 
per 1,000 adult women, respectively.  
Only three studies were found focusing on incidence rates for some of these drug 
groups in children. The incidence rates for antipsychotics ranged from 0.3 to 3.7, while 
the other rates were all from one Icelandic study with incidence rates of 8.0 for 
antidepressants, 1.3 for anxiolytics and 2.5 for hypnotics per 1,000 children (table 7). 
The incidence rates for children in Iceland are probably not representative for other 
countries as prevalence rates from Iceland differ from the figures in other countries. 
 37 
Table 7  Incidence rates of psychotropic drug use per 1,000 inhabitants in 
different countries and years  
Author  Country Year Population  Method / Material Rate 
Adults  Antipsychotics 
Mirandola 
(12) 
Italy 2002 2,6 million, all ages 
Province of Veneto 
Prescription database of 
reimbursed drugs 
2.6 
men   2.2 
women   2.9 
Trifiro  
(69) 
Italy 2002 465,000 from  
320 GPs  
aged 15 or older 
The Health Search Database  10.9 
Kaye  
(68) 
UK 2000 Patients from GPs 1.4-
1.7 million 
aged 10 or older 
The General Practice 
Research Database  
men   3.3 
women   5.0 
 Antidepressants 
Raymond  
(78) 
Canada 2004 4.1 million citizens, 
British Columbia 
The British Columbia 
PharmaNet system 
4.2 
Rosholm  
(75) 
Denmark 1997 Population of Fünen, 
470,000  
aged 20 or older  
The Odense Pharmaco - 
epidemiological Database  
13.0  
Isacsson 
(72) 
Sweden 1996 Representative sample, 
18,000 
The prescription database  
of Jämtland  
13.3 
men   10.9 
women   15.7 
Hansen  
(13) 
Denmark 1998 Population of Fünen, 
470,000 
aged 18 or older 
The Odense Pharmaco - 
epidemiological Database 
17.0 
Meijer  
(73) 
The 
Netherlands 
2001 850,000  
aged 18-85 
The PHARMO 
database 
SSRI  
TCA  
14.5 
5.8 
 
Trifiro 
(76) 
Italy 2003- 
2004 
142,346 patients from 
119 GPs in Italy 
aged 15 or older 
The Arianna database  30.6 
 Hypnotics 
Hausken  
(15) 
Norway 2006 All inhabitants  
4.6 million 
aged 18 to 69 
The Norwegian  
Prescription  
Database 
Z- 
hypnotics 
BZD- 
hypnotics 
men   18.4 
women   29.6 
men     1.3 
women     1.3 
Children and adolescents  Antipsychotics 
Rani  
(70) 
UK 2005 789 467 patients aged 
19 or younger 
The General Practice 
Research Database 
0.3 
Kalverdijk  
(71) 
The 
Netherlands 
2005 119,612 patients aged 
19 or younger 
The Inter-Action database 1.6 
Zoega  
(64) 
Iceland 2007 All residents (n not stated)  
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
3.7 
 Antidepressants 
Zoega  
(64) 
Iceland 2007 All residents (n not stated)  
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
8.0 
 Anxiolytics 
Zoega  
(64) 
Iceland 2007 All residents (n not stated)  
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
1.3 
 Hypnotics 
Zoega  
(64) 
Iceland 2007 All residents (n not stated)  
aged 17 or younger 
The Medicines Registry on 
prescribed drugs in Iceland 
2.5 
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Distribution among physicians  
Some studies have analyzed various physician groups’ proportions of psychotropic 
drug prescribing. GPs issued the vast majority of prescriptions in all but one study 
(table 8), while psychiatrists prescribed from 5.7 to 22.5 %.  
Some studies discussed the differences in choice of drug types, showing that GPs more 
often prescribed first generation antipsychotics (85-86) than psychiatrists, and that 
psychiatrists more often prescribed higher doses of antidepressants than GPs (73, 87).  
A French study compared patients identified as depressed by GPs and psychiatrists. 
Psychiatrists’ patients were younger, more often urban, educated, met DSM-IV criteria 
for depression, had been hospitalized for depression and were younger at onset of 
depressive problems than the GPs’ patients. No difference was found for psychiatric 
and somatic comorbidity, suicide attempt or severity of current depression. Compared 
to GPs, psychiatrists more often prescribed tricyclic and non-SSRI non-tricyclic 
antidepressants, and used more prolonged treatment duration. GPs' patients received 
less psychotherapy and more non-conventional treatment as homeopathy, acupuncture, 
herbal medicine etc. The authors concluded that the differences between practices of 
GPs and psychiatrists appeared to reflect the organization of the French health care 
system more than the competence of the providers (88).  
A study from Sweden found an increased use of antidepressants and fewer suicides in 
the county of Jämtland, after a primary care educational program on treatment of 
depression (89), repeating an earlier study from Gotland (90). 
An American study comparing the care given by primary care providers and 
psychiatrists to patients with anxiety concluded that nearly half the primary care 
patients with anxiety disorders were not treated. However, when they were treated, the 
care received from primary care physicians and psychiatrists was rather similar (91).  
Another American study about the prescribing practices of physicians caring for 
children with mental illness found no significant differences between psychiatrists and 
primary care physicians in psychotropic prescribing practices (92).  
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Table 8  Proportion of dispensed prescriptions of psychotropic drugs,  
by prescriber group 
     % of dispensed prescriptions 
Author Country Year Population  Method / Material GPs Psychiatrists Others 
Psychotropic drugs (prevalence data) 
Ohayon  
(93) 
UK 1994 4,972,  
aged 15 or older 
Telephone 
survey 
> 80   
Antipsychotics (prevalence data) 
Hamann 
(86) 
Germany 1999-
2001 
25 million customers  The statutory 
health insurance 
60 34* 6  
Ohayon 
(59) 
France, Italy 
Germany, UK 
1993-
1997 
18,679 
aged 15 or older  
Telephone 
survey 
31.7 22.5 45.8 
Antidepressants (prevalence data) 
Ohayon  
(59) 
France, Italy 
Germany, UK 
1993-
1997 
18,679 
aged 15 or older  
Telephone 
survey 
55.8 15.4 28.8 
Percundani  
(94) 
Italy  2001 9 million residents, 
Lombardy 
The Regional 
Administrative 
Database  
84.9 –  
91.2 
  
McManus  
(87) 
Australia 2000 88 % of dispensed 
antidepressant in 
Australia (n not stated)  
Health Insurance 
Commission 
claim records 
86  10  4  
Antidepressants (incidence data) 
Verdoux  
(95) 
France 2005-
2007 
19,975 
aged 18 or older 
Social Security 
Insurance 
database  
80.9 5.8 13.3 
Henriksson  
(96) 
Sweden 1995 18,000 
Representative 
sample  
The prescription 
database of 
Jämtland  
76 14  10 
Anxiolytics (prevalence data) 
Ohayon 
(59) 
France, Italy 
Germany, UK 
1993-
1997 
18,679 
aged 15 or older  
Telephone 
survey 
69.8  6.1  24.1 
Hypnotics (prevalence data) 
Ohayon 
(59) 
France, Italy 
Germany, UK 
1993-
1997 
18,679 
aged 15 or older  
Telephone 
survey 
81.5  5.7 12.8 
* Psychiatrists, neurologists and psychotherapists 
 
The cited studies confirm extensive use of psychotropic drugs. Especially the use of 
antidepressants has increased substantially in most high-income countries since the 
early 1990s. The choice of drugs has changed from older and cheaper to newer and 
more expensive drugs. The studies have shown that most of the psychotropic drugs are 
prescribed by GPs, but no detailed scientific information exists about the extent to 
which GPs initiate psychotropic drug treatment. Neither is any detailed analysis found 
regarding the relative contribution of different prescribing groups when it comes to the 
different drug groups for patients of different ages. Such information is relevant 
because drugs are widely used to treat psychiatric problems.  
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It is important to examine the situation in Norway since prescription practices are 
likely to differ between countries, and few studies have been performed with this 
focus. The four psychotropic drugs groups included in this study constituted 7.7 % of 
expenses for drug use in Norway in 2005 (97). The wholesale figures in Norway, 
measured as DDD per 1,000 inhabitants per day are shown in figure 2.  
(Department of Pharmacoepidemiology at the Norwegian Institute of Public Health, 
personal information). 
Figure 2  Wholesale figures for psychotropic drugs in Norway 1990-2010 
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The quality and the capacity of the health care system for handling mental problems 
are prioritized areas in the health services.  
Knowledge about prescribing patterns in different parts of the healthcare system is a 
prerequisite to improve the quality of psychotropic drug treatment. The impact from 
different parts of the health care system on the psychotropic drug use is essential 
information for the authorities to manage the health services in a proper way, and the 
government has requested more research on the subject of pharmacotherapy (98).  
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2. The present study 
This study examines the use of psychotropic drugs in the general Norwegian 
population during the years from 2005 to 2008.  
2.1 Aims of the papers included in the thesis  
The more specific objectives of the study were to examine the incidence and 
prevalence rates, and the distribution of psychotropic drugs in general practice versus 
specialist care.  
The aims of each paper were as follows;  
- Paper I To analyze psychotropic drug use in the general population of Norway 
in 2005, with special emphasis on prescribing patterns in primary and 
secondary care.  
- Paper II To examine the incidence rates for antipsychotic and antidepressant 
drug treatment in the general population of Norway, and to explore to 
what extent the treatment was initiated by GPs, psychiatrists or other 
physicians, respectively. 
- Paper III To examine incidence rates for treatment with addictive anxiolytics 
and hypnotics in Norway, the proportions initiated by GPs, 
psychiatrists or other physicians, and the course of the treatment 
among incident users during a 3.5 year period of follow up. 
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2.2 Material and methods  
2.2.1 Data sources and study population 
The research is based on data from the Norwegian Prescription Database (NorPD),  
the General Practitioner Database at Norwegian Social Science Data Services, and 
information about the general Norwegian population from Statistics Norway.  
The Norwegian Prescription Database, NorPD 
The Norwegian Prescription Database was established in 2004 and is maintained at the 
Norwegian Institute of Public Health (99). It is a national health register with the aim 
to collect and process data on drug consumption by humans and animals in Norway. 
The data is used to map usage and monitor trends in the Norwegian drug consumption. 
Health authorities receive statistical information needed for quality control of drug use 
and for management and planning of the health care system. In addition, the NorPD is 
an important resource for research, especially for pharmacoepidemiological studies.  
The register contains information on all prescriptions fully paid for by patients, as well 
as those reimbursed by the government, dispensed at all Norwegian pharmacies to 
community-dwelling individuals from 1 January 2004. Detailed information about the 
dispensed drugs and basic demographic information about patients and prescribers are 
included (97). The information is clearly connected to each physician and patient by a 
unique pseudonym code. Dispensed prescriptions from each physician and redeemed 
prescriptions to each patient can thus be followed over time. The privacy of the 
individual is strictly protected, and it is illegal to try to reverse the information to 
reveal the identity of patients or physicians.  
The database contains no information about drugs purchased without prescription 
(over the counter, OTC), or the medications dispensed to institutionalized individuals 
in hospitals and nursing homes, or those who are in prison. 
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The Regular General Practitioner Database  
When the national regular GP scheme was implemented in 2001, the Regular General 
Practitioner Database was established at the Norwegian Social Science Data Services 
(50). The Regular GP Database contains monthly updated information on individual 
GP’s patient population, derived from the Norwegian Labour and Welfare Services, 
Statistics Norway and the Norwegian Social Science Data Services.  
Statistics Norway  
Statistics Norway is the central bureau of statistics in Norway and was established in 
1876. The Agency has primary responsibility for meeting the need of statistics in the 
Norwegian society. In this project, statistics on the general population were obtained 
from Statistic Norway and used to establish denominators in the analysis of the 
different rates concerning gender and various age groups.  
Variables  
The variables extracted from NorPD included data from all prescriptions of 
antipsychotics (ATC group N05A), anxiolytics (N05B), hypnotics (N05C) and 
antidepressants (N06A) from 1 January 2004 until 31 August 2009.  
GPs’ unique pseudonym codes and information about their enlisted patient populations 
in February, May, August and November in each year were collected from the Regular 
GP Database.  
Data from NorPD and from the Regular GP Database were merged by Statistics 
Norway, using each patient’s and prescriber’s pseudonym code, enabling us to analyze 
the data at the individual level, while personal anonymity was ensured. The variables 
extracted from the different registers and included in the study database are shown in 
table 9. 
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Table 9  Variables extracted to the study database  
The Norwegian Prescription Database 
Drugs ATC code Trade name Generic name 
Redeemed prescriptions Dispensing date Volume (DDD) Drug formulation 
Patients Pseudonym code Gender  
 Birth year and month Death year and month  
Prescribers Pseudonym code Gender Birth year 
 Profession Specialties  
The Regular General Practitioner Database 
Prescribers Pseudonym code  
Enlisted population  Date  Number of women Number of men 
 Patient age groups  (<10, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, ≥ 80) 
Statistics Norway  
General population Date Birth year  
 Population of men Population of women  
 
2.2.2 Statistical analysis 
The chi-square test was used to compare proportions. P values of < 0.05 were 
considered statistically significant. Logistic regression analyses were used to analyze 
the associations between binary outcome variables and several independent variables. 
Effect estimates were presented as odds ratios (OR) with 95 % confidence intervals 
(CI).  
In Paper I, the whole population is included, and therefore the results are shown 
without confidence intervals or p-values.  
Logistic regression analyses were performed to examine associations between selected 
variables; Paper II: gender, age groups, prescriber groups, and the use of older 
antipsychotics or antidepressants and Paper III: gender, age groups, drug volume in 
first quarter, drug redeemed at index day, prescriber groups, prescribers gender, 
prescribers age groups and prescribers prescribed volume in total, and the risk of being 
long-term or heavy user of addictive anxiolytics and hypnotics, respectively.  
A follow-up analysis of the cohort of new users was carried out in Paper III, presented 
as percentages of the enrolled patients who redeemed at least one prescription in each 
subsequent quarter (91 days), assigned to the prescriber group that initiated the 
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treatment. Patients who died in one quarter were excluded from the analysis of the 
next quarter, i.e. the denominator was the number of patients who were still alive at the 
beginning of each quarter. 
STATA software version 9.2 (Stata Corp., College Station, TX, USA) and the Vassar 
Stats website for statistical computation (100) were used.  
2.2.3 Ethics  
The Regional Committee for Medical and Health Research Ethics, the Directorate of 
Health, the Norwegian Labour and Welfare Services, and the Norwegian Data 
Inspectorate all approved the study.  
 
 46 
2.3 Synopsis of papers 
Paper I  
Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general 
population in 2005: data from the Norwegian Prescription Database. 
Pharmacoepidemiology and Drug Safety 2009;18:572-8. 
Objectives: 
To determine the prevalence rates of psychotropic drug use and the distribution of the 
prescribing among GPs, psychiatrists and other physicians in Norway. 
Material and methods: 
Information about all prescriptions to community-dwelling persons of antipsychotics, 
anxiolytics, hypnotics and antidepressants redeemed at all pharmacies in Norway in 
2005 was extracted from the Norwegian Prescription Database and merged with data 
about all GPs in the same period from the Regular GP Database at the Norwegian 
Social Science Data Services. Information about the general population was collected 
from Statistics Norway. 
Results: 
One year prevalence rates per 1,000 inhabitants were 153 for use of any psychotropic 
drugs, 24 for antipsychotics, 60 for antidepressants, 62 for anxiolytics, and 79 for 
hypnotics. The rates increased with patients' age and were considerably higher for 
women than men. GPs prescribed 80 % of the medications, psychiatrists 5 % and other 
physicians 15 %. Psychiatrists prescribed 32 % of the psychotropic drugs to patients 
younger than 20. The proportion prescribed by psychiatrists declined rapidly with 
patients’ age and was about 2 % of the prescriptions to patients aged 60 or older. 
Conclusions: 
GPs issued the majority of prescriptions of antipsychotics, anxiolytics, hypnotics and 
antidepressants, and the proportion increased with patients’ age. Consequently, the 
quality of pharmacological treatment for mental health problems for adults relies 
mainly on GPs.  
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Paper II  
Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics 
and antidepressants in general practice and specialist care in Norway.  
Acta Psychiatrica Scandinavica 2011;123:459-65. 
Objectives: 
To reveal the incidence rates of antipsychotic and antidepressant drug use and to what 
extent such treatment is initiated by GPs, psychiatrists or other physicians in Norway.  
Material and methods: 
Information on all prescriptions of antipsychotics and antidepressants redeemed at all 
pharmacies in Norway from 1 January 2004 until 31 August 2009 was extracted from 
the Norwegian Prescription Database and merged with data about all GPs in the same 
period from the Regular GP Database. The study population included all patients who 
redeemed at least one prescription of an antipsychotic and/or antidepressant drug 
during 2008, provided that they did not release drugs from the same therapeutic 
subgroup during the 4 year period from 2004 to 2007. Information about the general 
population was collected from Statistics Norway. 
Results: 
One year incidence rates per 1,000 inhabitants were 3.4 for antipsychotics and 8.6 for 
antidepressants. The rates increased with patients' age, except for the age group 60-69 
years. Women had higher incidence rates than men but the differences between 
genders were less pronounced for antipsychotics.  
GPs initiated the treatment with antipsychotics for 58 % of the patients, and with 
antidepressants for 73 %, while the figures for psychiatrists were 15 % and 6 %, 
respectively. Patients younger than 20 years got their first prescription of 
antipsychotics from a psychiatrist in 47 % and of antidepressants in 26 % of the cases.  
The proportion of patients who got started their treatment by a psychiatrist declined 
rapidly with patients’ age, while the GPs’ contribution to initial prescribing increased 
considerably with patients’ age.  
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Psychiatrists issued second generation antipsychotics to 65 % while the other groups 
of physicians prescribed first generation antipsychotics to more than 70 % of the 
patients. As regards antidepressants, other specialists provided older antidepressants to 
63 %, while physicians without specialty and GPs prescribed newer antidepressants to 
more than 65 %, whereas psychiatrists issued newer antidepressants in 88 %.  
Of the new users of antipsychotics, 57 % redeemed only one prescription during 2008 
and a follow-up period of 8 months. The corresponding figure for antidepressants was 
33 %. Patients were more likely to release more than one prescription if the initial drug 
was a second generation antipsychotic or antidepressants, and if the treatment was 
initiated by a psychiatrist.  
Conclusions: 
GPs initiated the treatment of both antipsychotics and antidepressants to a majority of 
the patients, except for antipsychotics to patients younger than 20. Psychiatrists’ share 
was limited, especially among older patients. Consequently, efforts for quality 
improvement of pharmacotherapy in mental health need to involve GPs, and an 
increased focus from psychiatrists towards the increasingly ageing part of the 
population seems requisite. 
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Paper III  
Kjosavik SR, Ruths S, Hunskaar S. Use of addictive anxiolytics and hypnotics in a 
national cohort of incident users in Norway. 
European Journal of Clinical Pharmacology 2011 Sep 18. [E-pub ahead of print] 
Objectives: 
To examine the incidence rates of treatment with addictive anxiolytics and hypnotics 
in Norway, the percentage initiated by GPs, psychiatrists or other physicians, and the 
effect of selected variables on the risk among new users of becoming long-term or 
heavy users during a 3.5 years follow-up period. 
Material and methods: 
Information on all prescriptions of anxiolytics and hypnotics redeemed at all 
pharmacies in Norway from 1.January 2004 until 31.August 2009 was extracted from 
the Norwegian Prescription Database and merged with data about all GPs in the same 
period from the Regular GP Database at the Norwegian Social Science Data Services. 
The study comprised only anxiolytics and hypnotics that are considered addictive by 
the Norwegian Medicines Agency, and prescribed as oral formulations. Included in the 
study were all patients who redeemed one or more prescriptions of such drugs in 2005, 
provided that they did not redeem any of these drugs during 2004. The day of the first 
redeemed prescription of anxiolytics or hypnotics was defined as the index day for 
each person, and all prescriptions redeemed in the next 14 quarters (3.5 years) were 
included in the follow up analysis. Patients who redeemed prescriptions only during 
the first quarter and received a total volume of ≤30 DDD were defined as short-term 
users. In addition, we defined patients as long-term users if they redeemed 
prescriptions in ≥3 quarters in a row and received >180 DDD in total during the three 
quarter period, and heavy users if they received an average of ≥3 DDD/day during the 
quarter with highest redeemed drug volume. 
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Results: 
One-year incidence rates per 1,000 inhabitants were 18.2 for anxiolytics, 24.5 for 
hypnotics, and 35.4 for anxiolytics and hypnotics combined. The incidence rates 
increased considerably with patients' age and were higher for women than men in all 
age groups, except those aged 80 years and older who received hypnotics.  
Patients aged 19 or younger received their first prescriptions of anxiolytics and 
hypnotics from a GP in 37.5 % and 64.9 % of the cases, while psychiatrists provided 
5.0 % and 9.8 %, respectively. Adults aged 20 to 39 years received their first 
prescription of anxiolytics and hypnotics from a GP in 72.2 % and 72.0 % of the cases, 
and from a psychiatrist in 5.0 % and 5.5 %, respectively, but psychiatrists’ share 
declined rapidly with increased patients’ age, and accounted for less than 2 % in 
patients aged 60 and older.  
Of the cohort of new users, 30.8 % received short-term treatment, 11.8 % became long 
term-users, and 1.4 % became heavy users. 
When adjusted for other variables, the strongest predictor of both long-term and heavy 
use emerged to be the total drug volume redeemed during the first quarter. Most long-
term users and heavy users received their first prescription from a GP, but the 
individual risk of both long-term use and heavy use were highest if the treatment was 
initiated by a psychiatrist. The risk of heavy use was highest among males aged 20 – 
39 years and declined with higher age, while the risk of long-term use increased with 
patients’ age. 
Conclusions: 
The prescribing strategy towards incident users seems to be crucial to prevent long-
term or heavy use. In order to prevent inappropriate drug use, there is a need for 
implementation of relevant guidelines, and systems for structured clinical audit, 
especially in general practice.  
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2.4 Discussion  
The three papers have different objectives, but are based on a common comprehensive 
research database and closely related. To our knowledge, this is the first study that 
analyzes different physician groups’ contribution to the prescription of various 
psychotropic drugs in more detail. Combining the results from the sub-studies reveals 
even more understanding of the prescribing of these drugs. The relative proportions of 
the four drug groups dispensed to new users by GPs, psychiatrist and other physicians 
are revealed by combining Paper II and Paper III. Combinations of results from all 
the papers make it possible to estimate average treatment duration of the four drug 
classes by age. 
2.4.1 Discussion of each main finding 
Prevalence rates 
The prevalence rates per 1,000 were 153 for psychotropic drugs, 24 for antipsychotics, 
60 for antidepressants, 62 for anxiolytics and 79 for hypnotics in the Norwegian 
population in 2005 (Paper I).  
This study is based on the entire Norwegian population and covers all age groups, 
while many other studies focus on either children and adolescents or adults. It is 
important that results from different papers must be considered according to the ages 
they cover to be compared in a proper manner.  
Comparison with other studies in adults  
The prevalence rate of psychotropic drug use in adults in Norway is higher than in 
other countries (57-61).The same is true for antipsychotics (12, 57, 59-61, 65-68) and 
hypnotics (15, 59), while higher prevalence rates for anxiolytics has been shown in 
France (59), and for antidepressants in the United States (35) and in New Zealand (80).  
Several aspects may explain some of the differences. Many studies were based on 
surveys of sampled cases (14, 35, 57-61, 67, 72, 74, 82). Such studies may be affected 
of bias, e.g. recall bias in interview surveys or selection bias of the sample. In addition, 
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some studies estimated point prevalence rates while our study analyzed one-year 
prevalence rates, and higher figures may then be anticipated.  
In the case of antipsychotics, two Italian studies (12, 65) were based on databases 
covering large populations in provinces, but only reimbursed prescriptions. Second 
generation antipsychotics were not covered by the reimbursement system in Italy until 
2001, and the studies analyzed data from the year of 2001 and 2002. An impact of this 
legislation is likely.  
GPs’ populations were the basis for some studies (14, 66, 68-69, 76). Such samples 
may be biased compared to the general population, as healthy individuals do not 
necessarily see a GP, and more seriously ill patients may in some countries be treated 
in secondary health care only. 
Databases covering the whole population of counties or provinces were used in six 
studies focusing on use of antidepressants (65, 75, 77-80). The differences between 
these studies may reflect the trend in use of antidepressants, as the older ones have 
lower rates (65, 73, 75), while the three studies from 2002 to 2004 (77-79) are in line 
with the Norwegian results, and the newest from 2007 (80) found higher rates.  
In addition, real differences in use of psychotropic drugs between countries are 
probable, and may explain variations to some extent.  
Comparison with other studies in children and adolescents  
Studies of psychotropic drug use among children and adolescents included different 
drug groups and made comparisons difficult.  
As regards antipsychotics, prevalence rates in Norway were higher than in Italy and 
the United Kingdom (62, 70), and lower than in Iceland and the Netherlands (64, 71). 
Lower rates were found in Italy, Germany, and Denmark than in Norway for 
antidepressants (62-63, 81), while rates were higher in the Netherlands, Iceland, 
Canada and in the United States (30, 63-64, 81). The prevalence rates for anxiolytics 
and hypnotics were in line with the Netherlands when analyzed together (63), but 
higher than the rates in the United States (30). Separately, the Norwegian rate of 
 53 
anxiolytic use was higher than the Icelandic, while the opposite was the case for 
hypnotics (64).  
Morbidity and treatment gap 
Reviews on prevalence rates of mental disorders in Europe in 2005 and 2010 (101-
102) show similar results as regards the main psychiatric disorders, i.e. no substantial 
increase or decrease were identified. According to the “best estimate” from the latest 
report, anxiety disorders were most frequent, with a one-year prevalence of 14 %. 
Mood disorders were the second with a 6.9 % prevalence of major depression and  
0.9 % of bipolar disorder. Non-organic insomnia had an estimated prevalence of 7.0 
%, but insomnia is often a major symptom of other disorders, and the authors assumed 
that this figure was substantially overestimated. Somatoform disorders had a 
prevalence of 4.9 %, psychosis 1.2 %, and eating disorders 0.4 %.  
According to WHO (103), the treatment gap between patients with various psychiatric 
disorders and the share that received treatment in Europe was estimated to 18 % for 
schizophrenia, 25 % for obsessive compulsive disorder, between 40 and 50 % for 
major depression, dysthymia, bipolar disorder, and panic disorder, above 60 % for 
generalized anxiety disorder, and more than 90 % for alcohol abuse and dependence 
disorder. 
Interpretation  
Clinical and diagnostic information were not available in the study, and yet the results 
have led to some thoughts about the prescribing practice. Compared to the prevalence 
estimates of psychosis and bipolar disorders, the prevalence rate for antipsychotic use 
of 2.4 % seems high. One explanation would be that a higher percentage of patients 
with psychosis or other severe psychiatric disorders receive treatment in Norway than 
estimated for Europe. However, the 57 % proportion of patients who redeemed only 
one prescription of antipsychotics supports the assumption that antipsychotics often 
are used for non-psychotic or less severe mental problems. Such an explanation is 
supported by trends in antipsychotic drug use in other countries, revealing expansion 
of indication for use and increased off-label prescribing of these drugs (31).  
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The proportion of the patients who redeemed several prescriptions of antipsychotics is 
more in line with the prevalence rate of psychosis.  
According to a Canadian study (38), a third of antidepressants were prescribed for 
reasons other than depression, as generalized or other anxiety disorder, sleep problems, 
musculoskeletal conditions, migraine, and chronic pain. Assuming similar prevalence 
of major depression in Norway as estimated for Europe, and a corresponding 
prescribing practice in Norway as in Canada, i.e. two-thirds of the antidepressants used 
for depression, the gap in drug treatment for depression in Norway is close to the 
WHO-estimated value for Europe. 
The difference between the prevalence rate for use of anxiolytics (6.2 %) and the 
estimated rate for anxiety disorders (14 %) is much larger. Anxiety may range from 
mild complaints to disabling mental illness, and perhaps some persons included in 
studies have confirmed anxiety problems although they would deny a need for 
treatment. Regarding treatment, other drugs than anxiolytics and non-pharmacological 
treatment are primarily recommended for these disorders, since patients often need 
long-term treatment, while anxiolytics are recommended for short-term treatment only 
(104). Since this study lacks clinical information and it is impossible to use the figures 
from this study to assess the treatment provided patients with anxiety disorders in 
Norway.  
Insomnia is a common symptom of various mental disorders. In such cases, the sleep 
disturbances may wane when the primary disorder is treated properly, although 
residual sleep problems are relatively common. Non-pharmacological treatment of 
insomnia has shown better results than drugs in some studies (4), and hypnotics are 
only recommended for short-term use. The prevalence for use of hypnotics was 7.9 %, 
the highest rate among the four drug groups, and it seems evident that hypnotics are 
used too widely.  
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Incidence rates  
The incidence rates per 1,000 were 3.4 for antipsychotics and 8.6 for antidepressants 
(Paper II), and 18.2 for anxiolytics, 24.5 for hypnotics, or 35.4 for anxiolytics and 
hypnotics combined (Paper III). The studies were based on the entire Norwegian 
population and covered all ages.  
Few papers were found revealing incidence rates for psychotropic drug use, and most 
were focused on either children and adolescents, or adults.  
Comparison with other studies in adults  
Two Italian studies analyzed the incidence rates of antipsychotic drug use, with quite 
different results; 2.6 per 1,000 and 10.9 per 1,000 (12, 69). Both studies used a one-
year baseline period to exclude prevalent users, and analyzed prescriptions to new 
users in 2002. The first study was based on the whole population of a province, but 
only reimbursed prescriptions were included. The other used a GP based database of 
patients aged 15 or older. Differences in the databases and in the age of enrolled 
patients might explain the variation in the results, and clearly demonstrate the 
importance of such methodological differences.  
A study from the United Kingdom, also based on a GP database, used a two year 
baseline period to exclude prevalent users. Patients aged 10 or older were included, 
and the results were rates of 3.3 per 1,000 for men, and 5.0 per 1,000 for women (68).  
Incidence rates of antidepressants were found in six studies of which four used large 
population based databases (13, 73, 75, 78), one was a representative sample of a 
county (72), and one used a GP based database (76). The incidence rates ranged from 
4.2 per 1,000 to 30.6 per 1,000. The highest rate was from a GP based database in Italy 
(76), and as discussed for antipsychotics, the results are probably not representative for 
the general population. The Canadian study (78) included all ages, and analyzed the 
incidence rates year by year during the period from 1998 to 2004. The results show a 
maximum incidence rate in 1999 of 12.4 per 1,000, which declined to 4.2 in 2004, 
although the prevalence rates increased in the period.  
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A Dutch study has estimated separate incidence rates for tricyclic antidepressants and 
SSRI, making comparison more difficult as the information about the combined rate is 
lacking. The incidence rates in the other studies conducted between 1996 and 2001 
ranged from 13.0 to 17.0 per 1,000 among adults. Based on adults aged 20 or older, 
the Norwegian incidence rate in 2008 was 11.4. The difference in incidence may be 
related to different years of observation, but differences in the prescribing trends in the 
countries are probable. 
As regards anxiolytics and hypnotics, only one Norwegian study was found assessing 
incidence rates, but for hypnotics only (15). It was based on the same database as this 
project, but included only patients between 18 and 69 years with data collection from 
2006. This study used data from 2005, but when comparing the same ages, the results 
were in line.  
Comparison with other studies in children and adolescents 
Only three studies were found, assessing the incidence rates of such drug use in 
children and adolescents. In a Dutch study of antipsychotic use based on a large 
database representative for the general population (71), the rate was twice the 
Norwegian rate, while a study from the United Kingdom based on GP data (70), had 
half the Norwegian rate. An Icelandic study (64) revealed incidence rates for all the 
four classes of psychotropic drugs. The rates were nearly five times higher than the 
Norwegian results for antipsychotics and antidepressants, while the rates for 
anxiolytics and hypnotics combined were in line with our study. 
Interpretation  
The studies revealed that new users were introduced to anxiolytics and/or hypnotics 
four times as often as to antidepressants and ten times as often as to antipsychotics. 
Anxiolytics and hypnotics relieve symptoms effectively, but with uncertain long-term 
treatment effect. Patients, who have experienced benefit of these drugs, often demand 
extended use even though the drugs are potentially addictive. As only 30.8 % received 
short-term treatment as recommended, our study confirms sustained use for a majority 
of patients. Despite the lack of clinical information, it seems likely that too many 
patients use them in a too long period.  
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Clinical information is needed to assess the appropriateness of drug treatment. 
However, the share of the patients who redeemed only one prescription were 57 % for 
antipsychotics, and 33 % for antidepressants, even though longer treatment periods are 
recommended for most indications. Increased off-label prescribing and use in other 
indications than psychosis and depression may be the reason. Consequently, it seems 
to be a potential for quality improvement also regarding the use of antipsychotics and 
antidepressants. 
A large treatment gap is estimated by WHO between patients with different psychiatric 
disorders and the portion who are treated (103). To improve the situation, patients in 
need for treatment should be diagnosed and treated in an appropriate manner. GPs are 
closest to the patients and have the best opportunity to do so, but the large gap for most 
mental disorders verify a potential for improvement. 
Distribution by age and gender 
Prevalence rates (Paper I) and incidence rates (Paper II and Paper III) increased by 
age. Women used more psychotropic drugs than men at most ages and for all four drug 
classes, even though the differences were less regarding antipsychotics.  
Comparison with other studies 
Our findings are in line with age and gender distribution in other studies of prevalence 
of psychotropic drug use (57-59, 61, 68, 75), and confirm the same trend among new 
users. The gender differences reflect the morbidity in men and women, as the ratio 
women / men are estimated to be ≥ 2 for major depression, anxiety disorders, 
somatoform disorders and eating disorders (102). The prevalence was higher for men 
than for women only for psychotic disorders and substance dependence disorders, 
mainly alcohol but also narcotic dependence, in line with two Norwegian studies (105-
106). No age group was more susceptible to mental disorders than others in the rural 
area in Norway (106), while the age group of 30-39 years was most at risk in the city 
of Oslo (105). The European review (102) found double rates for general anxiety 
disorder among patient aged 65 or older (3.4 %) compared to the age group 14-65 
years (1.7 %), while post-traumatic stress disorder and eating disorders declined by 
age.  
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Interpretation  
More women than men visit GPs, and do so more often than men in all age groups, 
except for children aged 10 or younger, and the oldest aged 80 years or older. In 
addition the number of visits increases by age (22). Thus, increased contact with the 
health care system may explain some of differences by age and gender. Another 
important difference between genders is the marked preponderance of males with 
alcoholic dependence disorders and the treatment gap is estimated to be above 90 % in 
this group. (103). It is documented that men with mental disorders may use alcohol as 
self-medication (107-109). Men with mental problems, hidden in the group of 
dependence disorders, may partly explain the differences between men and women 
regarding rates for mental disorders.  
Older age  
Data about individual drug use in nursing homes is not included in NorPD, and 
thereby unavailable in the study. The number of patients in nursing homes are 
approximately 41,000 (110) with a mean age of 86 years, and 71 % are women (111). 
Accordingly, the counter is too small in the analyses of drug use among older people 
as the patients in nursing homes are included in the denominator. Thus, the real 
incidence and prevalence rates among older people are even higher than shown. 
The increased use of psychotropic drugs by age is of concern. Older people are more 
susceptible to adverse side effects of drug use (47). Studies have shown that drug 
related problems caused more than 10% of hospitalizations (112). Women were more 
prone to side effects of drugs than men (113), and two third were patients aged 60 or 
older (114). Of the patients admitted to hospital due to adverse side effects, 
psychotropic drugs caused a minor but significant part. Patients often use psychotropic 
drugs together with other drugs and poly-pharmacy was shown to be an important risk 
factor by itself (114).  
Behavioral and psychological symptoms are prevalent among patients with dementia 
(115), and antipsychotics are often used to treat such symptoms, especially in nursing 
homes (17). Our study shows that such drugs is also commonly given to community-
dwelling older people, with the highest incidence rate in the group 80 years and older.  
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The significant use of older antipsychotics and antidepressants is especially of 
concern. First generation antipsychotics have stronger dopamine-blocking effects and 
have a higher risk for parkinsonism and tardive dyskinesias than the second generation 
antipsychotics. Antipsychotics have other important adverse effects too, and have been 
shown to increase morbidity and mortality among patients with dementia (116-117). 
Thus, the extensive use of antipsychotics, especially first generation antipsychotics 
among older patients, is in contrast to current recommendations (32, 118). The reasons 
for behavioral and psychological symptoms in dementia are multi-factorial. As shown 
in a recent study, proper treatment of pain may reduce the symptoms effectively 
among many patients (119). Thus, thorough clarification of the causes of such 
symptoms is important to avoid inappropriate use of psychotropic drugs.  
Antidepressants have been associated with several severe adverse reactions in older 
people. Tricyclic antidepressants are usually considered to be particularly harmful to 
elderly due to anticholinergic, anti-histaminergic, and antiadrenergic effects. In 
contrasts with current recommendations, the incidence rate for receiving older 
antidepressants increases with age (120). It is also shown an increased use of 
antidepressants with proximity to death in patients aged 65 or above (121).  
A recent study suggests that antidepressants in the elderly are associated with 
increased mortality, attempted suicide or self-harm, stroke and transient ischemic 
attack, seizures and more (122), and that the risks are higher in SSRIs compared with 
tricyclic antidepressants. Increased frequency of falls and fractures has also been 
revealed among people using antidepressants, but also in patients using anxiolytics and 
hypnotics (123-124).  
The high prevalence and incidence rates for psychotropic drug use among older people 
confirm a substantial potential for quality improvement of drug use in the geriatric 
population. Proper management and dosage of drugs are of great importance in these 
patients, and other therapeutic strategies and psychosocial interventions should be 
considered instead of or in addition to psychotropic drugs, whenever possible. 
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Distribution by prescriber  
One of the main objectives in this research was to analyze the distribution of the 
prescribers of psychotropic drugs. The results clearly demonstrate a difference 
between patients aged 19 and younger compared to the adults. Psychiatrists initiate 
(Paper II) and maintain (Paper I) an important part of the treatment with 
antipsychotics and antidepressants to children and adolescents. Pediatricians and 
neurologists have similar shares of the anxiolytic prescribing to these patients (not 
shown in tables), probably due to the use of BZD for somatic conditions, e.g. epilepsy 
and convulsions.  
In adults, the contribution of the GPs is striking, increasing from approximately 70 % 
to 80 % of the prescriptions of antidepressants, anxiolytics and hypnotics in patients 
aged 20-39 up to above 80 years, and slightly lower percentages for antipsychotics. 
Psychiatrists’ share declines rapidly with increasing age of the patients. Regarding 
antipsychotics and antidepressants the percentage decline from 44 % and 26 % to 
patients aged 19 or younger, to less than 6 % and 3 % to patients above 60, 
respectively. The psychiatrists’ share of prescriptions of anxiolytics and hypnotics was 
less than 8 % in the youngest, and declined to less than 1 % in patients above 60.  
Another interesting finding is the impact from other physicians. This group comprised 
more than 15,000 physicians compared to approximately 4,000 GPs and 1,350 
psychiatrists. Other physicians include all physicians in other fields than general 
practice and psychiatry, together with residents in psychiatry not approved as 
specialists during the studied period. They were responsible for the first prescription in 
approximately 20 % of the cases receiving antidepressants, anxiolytics and hypnotics, 
and around 25 % for antipsychotics among adults, regardless of age. The proportion in 
total is also remarkably constant, with around 12 % of the total dispensed prescriptions 
of antipsychotics and antidepressants and around 15 % of anxiolytics and hypnotics.  
Comparison with other studies 
A telephone survey from the United Kingdom (93) found the GPs’ proportion of 
dispensed psychotropic drugs to be above 80 % in 1994. Another telephone survey, 
analyzing the prescribing to approximately 19,000 patients in four countries from 1993 
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to 1997 (59), found the share from GPs to be 31.7 % for antipsychotics, 55.8 % for 
antidepressants, 69.8 % for anxiolytics and 81.5 for hypnotics, while the figures for 
psychiatrists were 22.5 %, 15.4 %, 6.1 % and 5.7 %, respectively. In a study from 
Germany (86) based on an insurance database covering 25 million people in 1999-
2000, the proportion of antipsychotics issued by GPs was 60 %, while psychiatrists 
and neurologists prescribed 34 %. As regards antidepressants, an Australian study (87) 
based on 88 % of dispensed prescriptions of antidepressants in 2000 revealed that GPs 
issued 86 % of the prescriptions while psychiatrists prescribed 10 %. The percentage 
from GPs was in line with this in an Italian study (94) based on a provincial database 
of 9 million inhabitants in 2001. The results above are all based on prevalence studies, 
and only two papers were found to analyze the distribution by prescribers of initial 
prescribing. A Swedish study of new users of antidepressants in 1995 based on a 
database of approximately 18,000 inhabitants (96), revealed the proportions to be 76 % 
by GPs and 14 % by psychiatrists, while a French study from 2005-2007 (95) 
analyzing the incidence of antidepressants to a population of around 20,000 aged 18 or 
older found the share to be 81 % from GPs and 6 % from psychiatrist.  
No other studies were found that analyzed the distribution in detail by age and gender, 
nor any that analyzed which prescribers who initiated treatment with antipsychotics, 
anxiolytics or hypnotics.  
Interpretation  
It seems reasonable that the patients with primarily mental health problems are mainly 
treated by GPs and psychiatrists, while the patients with mental problems secondary to 
somatic disorders are mainly treated by GPs and other physicians. From such a view, 
the difference between other physicians and psychiatrists is interesting. The proportion 
of psychotropic drugs prescribed by other physicians was quite stable regardless of 
age, while the share from psychiatrists decline rapidly with age, even though both 
prevalence rates and incidence rates for use of all the four psychotropic drug classes 
increased by age.  
 62 
It is not known how this distribution has been earlier, or if there has been a shift 
between different prescriber groups after the introduction of the new psychotropic 
drugs during the last two decades. However, in the national mental health reform (24), 
the government underlined a higher priority for children and young people in 
secondary health care. The inverse relation shown between the incidence and 
prevalence rates at different ages, and the share of patients who got their prescriptions 
from a psychiatrist, may reflect a high concordance to this priority. It also indicates a 
limited admission to secondary mental health care for older people. Drugs should not 
be a simple solution to mental problems. Improved collaboration between GPs and 
specialists, particularly regarding older patients, seems crucial, and the psychogeriatric 
field needs a higher priority in specialist health care. This is going to be even more 
urgent as the demographic situation in Norway is changing, and the proportion of older 
people increases.  
Relative distribution of the drug classes prescribed for new users 
The results from Paper II and Paper III can be combined. Then a new perspective is 
revealed regarding physicians’ prescribing practice. By summarizing the number of 
new users of antipsychotics, antidepressants, anxiolytics and hypnotics initiated by 
GPs, psychiatrists and other physicians, the relative distribution of the drug classes 
provided by the different physician groups to new users can be calculated (figure 3). 
Even though GPs issued the vast majority of psychotropic drugs to new users, and 
other physicians prescribed a small proportion, the distribution between the drug 
classes provided was similar. GPs and other physicians issued anxiolytics or hypnotics 
in three fourths of the cases when all ages were combined. GPs prescribed a slightly 
higher proportion of antidepressants and a correspondingly lower share of 
antipsychotics than other physicians, but the differences were minor. Psychiatrists’ 
contribution of redeemed prescriptions of anxiolytics and hypnotics to new users were 
less than 3 %, while the percentage for antipsychotics and antidepressants were 14.9 % 
and 6.3 %, respectively. However, the relative distribution of the drug groups provided 
by psychiatrists to new adult users was fairly evenly distributed between the four 
classes.  
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Figure 3  Relative distribution of the drug classes provided by the different 
physician groups to new users  
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The distribution was quite different among children and adolescents. Psychiatrists 
provided mainly antipsychotics and antidepressants, while other physicians prescribed 
mostly anxiolytics to this group. The latter is probably due to non-psychiatric 
indications of anxiolytics, i.e. epilepsy.  
No other study that had analyzed this distribution was found, so comparison with other 
studies was impossible.  
Interpretation  
The differences between the physician groups’ prescribing practices were smaller than 
one might expect. The epidemiology is quite different among patients visiting GPs 
compared to the patients referred to psychiatrists. The latter consist of patients with 
higher prevalence of mental disorders. Thus, it was expected that psychiatrists issued a 
higher proportion of antipsychotics and antidepressants to new patients than GPs and 
other physicians. The figures confirm such a difference, although it might have been 
expected to be even greater. The most unexpected result was perhaps the equally large 
proportion of new adult patients receiving anxiolytics, hypnotics, antipsychotics and 
antidepressants issued by psychiatrists. Paper III revealed that the risk for long-term 
or heavy use of anxiolytics and hypnotics were highest if treatment was initiated by a 
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psychiatrist, but the results gave the impression that psychiatrist prescribed anxiolytics 
and hypnotics to few new patients. Although the percentage was low, the total amount 
of new users of these drugs were much higher than for antipsychotics and 
antidepressants, and the actual number of new patients who received drugs from 
psychiatrists were rather similar regarding the four drug classes. 
Another unexpected result was the similarity in the proportion of anxiolytics and 
hypnotics issued by GPs and other physicians to new users. GPs are dealing with all 
kind of problems affecting the patients, both somatic and mental as well as social. 
Other physicians are mainly specialists and residents in somatic departments in 
hospitals, and mental health is secondary to their main tasks. It would be reasonable to 
expect that GPs had a practice more similar to psychiatrists than to other physicians, 
but the results show that this is not the case. Physicians perceiving mental problems as 
less important tasks may use less effort to uncover the underlying diagnoses, and be 
content with providing symptomatic treatment.  
Another assessment of the high share of symptomatic treatment with anxiolytics and 
hypnotics provided by GPs may be that the overall outcome is dominated by a high 
number of patients with mental symptoms caused by somatic or social problems, 
compared to patients with psychiatric disorders. However, GPs issued a larger 
proportion of antidepressants than other physicians, and prescribed mainly newer 
types, more like psychiatrists, while other physicians provided mainly older 
antidepressants, which may indicate that the treatment more often was given for other 
reasons than depression (Paper II).  
When data are aggregated in this way, it seems that physicians in Norway are trained 
in a similar manner and appear to give fairly similar treatment to their patients in 
average.  
Distribution of treatment duration 
The study lacks clinical information. Even information about prescribed dosage was 
unavailable. The ability to assess the duration of the treatment to each patient was thus 
limited, and subject to much uncertainty and interpretation.  
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Paper I revealed the prevalence rates and Paper II and Paper III the incidence rates 
of the four drug classes. By combining these results a new perspective is revealed, the 
average treatment duration.  
When the situation is in a steady state, the relation between incidence rate, prevalence 
rate, and average duration of treatment may be expressed as:  
Average duration  = Incidence rate  Prevalence rate  
 
Wholesale figures were rather stable between 2005 and 2008 regarding antipsychotics 
and anxiolytics, while antidepressants and hypnotics had some increase (34). By 
assuming a stable situation during the project period, the mean duration of the 
treatment given to each age group for each drug class could be estimated (figure 4). 
The average treatment duration has a rather similar and marked reduction with 
increased age in all four drug classes. The exact figures should be considered with 
some uncertainty, but the assumption seems acceptable, since the estimated average 
treatment duration is quite similar for anxiolytics and hypnotics, and for antipsychotics 
and antidepressants.  
Figure 4  Estimated average treatment duration for each drug class by age  
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A striking result of this analysis is the similar trend in all the four curves. Even though 
the recommended treatment duration for anxiolytics and hypnotics are less than four 
weeks, while antipsychotics and antidepressants normally are recommended as more 
prolonged treatment, the reality seems to be quite different. Comparison with other 
studies were impossible, as no similar results was found.  
Interpretation  
The decreased average treatment duration with increased age may be a result of a more 
cautious attitude among physicians to provide psychotropic drugs to young people. If 
only the more severe cases are treated among younger patients, the average treatment 
duration may be more prolonged. Conversely, if more people get drugs for less severe 
symptoms with increasing age, shorter average treatment duration will be 
understandable and expected. The high proportion of patients who redeemed only one 
prescription of antipsychotics (> 50 %) and antidepressants (> 30 %) (Paper II) may 
explain the shorter average treatment duration for these drugs. The share of the 
patients with long-term use may increase the figures for average treatment duration 
considerable. No clinical consensus has been found as regards definition of long-term 
or heavy use of anxiolytics and hypnotics, but variables of importance for the risk of 
long-term or heavy use of such drugs has been analyzed and discussed in several 
studies (83-84, 125-127). Both international and national guidelines recommend short-
term use only, e.g. less than four weeks (39, 128-131), but this study (Paper III) 
shows that only a third of the patients are treated in accordance with these 
recommendations, even in new users of today.  
The big difference between clinical practice and academic recommendations may 
question the appropriateness of the recommendations as in a paper from psychiatric 
practice in Italy (132). But other studies conclude that non-addictive drugs and non-
pharmacological treatment may give as good or better results than the addictive drugs 
in a longer perspective (4, 133), so short-time use of these drugs are still the 
recommended approach. Thus, the estimated average treatment duration is certainly 
not in accordance with the recommendations, and the analysis confirms a substantial 
potential for quality improvement regarding these drugs.  
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2.4.2 Methodological strengths and limitations  
The study is based on comprehensive information from three national data sources. 
The Norwegian Prescription Database delivered data about all prescriptions of 
psychotropic drugs from all pharmacies in the country dispensed to community-
dwelling inhabitants from 1.January 2004 to 31.August 2009. Less than 1 % of 
prescriptions were excluded due to missing data of some variables. The Regular GP 
Database provided complete information about all GPs and patients enlisted at each 
physician. Merging data from these universal databases together with information 
about the general population from Statistics Norway enabled us to create a 
comprehensive research database, capable of analyzing prevalence rates and incidence 
rates as well as the course of drug use regarding anxiolytics and hypnotics. Merging 
data from NorPD and the Regular GP Database also provided a unique opportunity to 
differentiate between prescriptions issued by GPs, psychiatrists and other prescribers. 
A rather strict definition was used to reveal one-year incidence rates for antipsychotic 
and antidepressant drug use, excluding patients receiving treatment during a 4-year 
baseline period. A less strict definition was used as regards new users of anxiolytics 
and hypnotics, but thus the course during a follow up period of 3.5 year could be 
analyzed.   
To our knowledge, this is the first nation-wide study analyzing the distribution of 
psychotropic drug utilization, i.e. use of antipsychotics, antidepressants, anxiolytics, 
and hypnotics, by different prescriber groups in more detail. This was completed 
regarding both prevalent users (Paper I) and incident users (Paper II and Paper III). 
No other studies were identified revealing incidence rates for anxiolytics, and few 
studies had shown incidence rates for other psychotropic drugs. No studies was found 
who analyzed the different prescriber groups’ practice as regard the relative 
distribution between the four drug classes issued to new users.  
However, several limitations should be taken into consideration.  
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Dispensed prescriptions were used as a proxy for drugs prescribed by the physicians, 
as well as for drugs consumed by the patients. The patients’ compliance is unknown, 
and may differ between patients treated by various physician groups.  
Limitations regarding the existing databases include the lack of individual information 
about medications prescribed for institutionalized patients. Nursing home residents and 
inpatients constitute a smaller part of the total population but their consumption of 
psychotropic drugs is significantly higher than among patients receiving home nursing 
services (134). Accordingly, the counter is too small and the denominator too large in 
the analysis, and the real incidence and prevalence rates among older people even 
higher than shown.  
The prescribed dosage of the dispensed prescriptions is not available in NorPD, as it is 
in the Swedish prescription database (135). NorPD includes information about 
prescribers’ specialties, but no information about physicians’ working field. 
Information from the Regular GP Database solved the problem to separate GPs from 
other physicians, but the distribution of physicians not working as GPs had to be based 
on assumptions. Physicians were defined as psychiatrists if they were approved as a 
specialist in psychiatry or child and adolescent psychiatry during the period covered by 
the study period, although this assumption may include some psychiatrists not working 
in clinical practice or in other fields. In addition, residents in psychiatry who did not 
fulfilled their specialty during the observed period, could not be distinguished from 
residents in other departments.   
Prescriptions covered by the national reimbursement system require diagnostic codes. 
However, the codes are considered to be quite inaccurate, and thus not included in the 
analysis in this study. Hopefully the quality improves so that the codes will be more 
useful in the future. Other clinical information was not available in NorPD, and 
according to current legislation, it is very difficult to achieve permission from the 
authorities to merge such information with data from NorPD. The lack of diagnoses 
and indications for drug treatment hampers investigation of patients’ morbidity, 
comparison between patient groups treated in different parts of the health care system, 
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as well as the assessments of prescribing quality. Thus, differences in prescribing 
patterns between the different prescriber groups may be confounded by indication.  
In lack of clinical information, examination of co-prescribing could be a source for 
more information about each patient. Such analyses have not been done in this project, 
but should be conducted in the future. 
A change in the legislation in 2009 allowed the Norwegian patient registry to collect 
data at the individual level. This register collect some information about all patients 
referred to secondary health care. The register may improve the possibilities in 
research, but still clinical data from primary care is unavailable. 
Researchers’ access to information from NorPD is strictly regulated. Researchers must 
just assume that the delivered data is correct, and have few opportunities to assess the 
quality correctness and of delivered information.  
In Paper I, lithium and prochlorperazine were included in the calculation of 
prevalence rates for antipsychotics. This was logical from a pharmacoepidemiological 
view as both the drugs are classified in the N05A group in the ATC system. Yet it may 
be otherwise from a clinical point of view, as the use of these drugs differs from the 
rest of the antipsychotics. It is also important to take this aspect into consideration 
when comparing the results with other papers.  
In Paper III, the incidence rate for anxiolytics and hypnotics may be overestimated 
due to a baseline period of only one year. Patients may have used anxiolytics or 
hypnotics earlier, but not during baseline. If the treatment was re-activated during our 
inclusion period, the patients were incorrectly recognized as new users. The same 
possibility exists for antipsychotics and antidepressants, but with a baseline period of 
four years, such an effect should be of little significance.  
No information was available about patients who have bought drugs legally abroad or 
illegally on the black market. Neither do we know the extent of false prescriptions. 
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2.5 Concluding remarks and implications  
This project has demonstrated that GPs not only prescribe the majority of psychotropic 
drugs, but also initiate the treatment to the majority of patients with mental health 
problems in Norway. Although mental health care comprises many other aspects than 
pharmacotherapy, it is apparent that GPs have a key function in the Norwegian mental 
health care services. The first recommendation from WHO to improve the mental 
health care, provide treatment in primary care, may be perceived as fulfilled.   
The second recommendation from WHO, make psychotropic drugs available, may 
also be perceived as fulfilled, as the project has proved that prevalence rates and 
incidence rates for psychotropic drug use are in line with or higher than in other high-
income countries.  
Through the mental health reforms initiated in 1997-1998 (23-24), the Norwegian 
government was in advance of WHO’s sixth recommendation from 2001, to establish 
national policies, programs and legislation. Thus this recommendation may also be 
perceived to be met.  
The demographic changes will result in a higher proportion of older inhabitants, and 
the demand for health care services will increase. The need for better working methods 
and improved use of resources is already a political issue and focused in the new 
health care reform, The Coordination Reform (136). It will be implemented in 2012, 
and the results remain to be seen.  
As this study confirms, the quality of the service to adults and older inhabitants 
depends on the GPs' knowledge and practice. A cost effective improvement of mental 
health care can only be achieved if GPs are an essential part of the effort. Accordingly, 
the government should have been concerned to ensure the quality of services provided 
to these patients in primary care. However, GPs were barely mentioned in the 
improvement reform of mental health services (24).  
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Thus, improved collaboration between GPs and specialists, particularly regarding 
older patients, seems crucial. In Sweden, short courses of GPs has reduced the suicide 
rate as well as the frequency of sick-leave due to depression in two different projects 
(89-90), and thereby confirmed the substantial potential for improvement of mental 
care in general practices. In Australia, new approaches with expanding roles for 
psychiatrists as educators and clinical mentors for GPs have been attempted (137-138). 
Different strategies should be tried out and evaluated to find cost-effective measures to 
successfully empower GPs to deal with mental problems in the best possible way. 
Prior to the establishment of the Norwegian prescription database, the Norwegian 
Medical Association, the Norwegian Pharmacy Association, the Norwegian Dental 
Association and the Norwegian Veterinary Association proposed jointly to establish a 
program for structured clinical audit to improve quality of drug prescribing in Norway. 
The proposal was aimed at a national prescription database, together with personal 
audit and counseling of prescribers.  
The NorPD was founded by the government in 2004, and the aims were determined to 
be: a) Map drug usage in Norway and monitor trends, b) Be a resource for research in 
order to see positive and negative effects of drug consumption, c) Give health 
authorities a statistical base for quality control of drug use and for steering and 
planning and d) Give prescribers a basis for internal control and quality improvements. 
NorPD is established as a provider of information about dispended prescriptions in 
Norway, and has met the first three purposes, even though the Norwegian prescription 
database has important limitations regarding research. Development of systems to 
obtain individual drug use in institutions and hospitals are highly desirable. In addition 
it is important to solve the need of clinical information, while personal anonymity is 
ensured. Clinical information is essential for further improvement and development of 
the research in this field.  
Another interesting new resource for information is the new electronic prescription 
program. Such information can easily be incorporated in the NorPD while personal 
privacy is assured. It can be a unique possibility to gain some more knowledge about 
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patients’ compliance with physicians’ recommendations, as figures can be obtains 
about prescriptions not redeemed. Such data are unavailable today.  
NorPD has cooperated with researchers in some quality improvement projects (139-
140), but an ongoing system for structured clinical audit and quality improvement of 
drug use has not been established. Although NorPD has credibility, it is unlikely that 
NorPD is suitable for such a task, as the impact of such an organization will depend on 
clinical knowledge, and close cooperation and communication with the physicians.  
This project reveals a relatively high use of first generation antipsychotics in primary 
care, a high proportion of patients who redeemed only one prescription of 
antipsychotics and antidepressants, and low correspondence between international and 
national guidelines and actual prescribing of addictive anxiolytics and hypnotics.  
GPs prescribe the vast majority of psychotropic drugs in all ages. Hence, the quality of 
pharmacological treatment is mainly dependent on the knowledge and practice of each 
GP. Improving mental health care is only achieved in a cost effective manner if GPs 
are a major part of the effort. 
Clinical information has not been available in the project, and consequently, the 
clinical impact is not known. However, the results support the proposal to establish a 
continuous program for clinical audit and quality improvement of drug use. If such a 
scheme is established, it will meet the seventh recommendation from WHO; develop 
human resources.  
In addition, it would be a great opportunity to improve research in primary health. If 
clinical information aimed for audit and quality improvement can be made available 
for researchers, pharmacoepidemiological studies and clinical research can make 
major advances. Such a system will thus provide a longed basis for clinical research in 
general practice, and meet the tenth recommendation by WHO, support more 
research.  
 73 
References 
1. Rangaswamy Srinivasa Murthy JMB, JoAnne Epping-Jordan, Michelle Funk Thomson 
Prentice, Benedetto Saraceno, Shekhar Saxena. Mental Health: New Understanding, 
New Hope: WHO2001. 
2. World Health Organization. mhGAP : Mental Health Gap Action Programme: scaling 
up care for mental, neurological and substance use disorders. Geneva: World Health 
Organization; 2008. 
3. Demertzis KH, Craske MG. Anxiety in primary care. Curr Psychiatry Rep. 2006 
Aug;8(4):291-7. 
4. Bjorvatn B, Sivertsen B, Oyane N, Nordhus IH, Pallesen S. [Insomnia]. Tidsskr Nor 
Laegeforen. 2009 Sep 10;129(17):1766-8. 
5. World Health Organization. The selection and use of essential medicines : report of the 
WHO Expert Committee, March 2009 (including the 16th WHO model list of essential 
medicines and the 2nd WHO model list of essential medicines for children). Geneva: 
World Health Organization; 2009. 
6. Kirkwood BR, Sterne, Jonathan A C, . Medical Statistics: Blachwell Science Ltd; 
2003. 
7. Sundar T. Ti år med ICPC i Norge Tidsskr Nor Lægeforen; 2002 [cited 2011 10.08.]; 
Available from: http://tidsskriftet.no/lts-pdf/pdf2002/1414-5.pdf. 
8. Mezzich JE. International surveys on the use of ICD-10 and related diagnostic 
systems. Psychopathology. 2002 Mar-Jun;35(2-3):72-5. 
9. The Ministry of Health and Care Services. National Health Plan for Norway (2007–
2010).  2007; Available from: 
http://www.regjeringen.no/Upload/HOD/Vedlegg/Engelsk/National%20Health%20Pla
n.pdf. 
10. Organisation for Economic Co-operation and Development (OECD). StatExtracts.  
2011 [cited 2011 15.07.]; Available from: 
http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH. 
11. United Nations Department of Economic and Social Affairs. Population Ageing. 2006 
[cited 2011 25.08.]; Available from: 
http://www.un.org/esa/population/publications/ageing/ageing2006.htm. 
12. Mirandola M, Andretta M, Corbari L, Sorio A, Nose M, Barbui C. Prevalence, 
incidence and persistence of antipsychotic drug prescribing in the Italian general 
population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf. 
2006 Jun;15(6):412-20. 
13. Hansen DG, Sondergaard J, Vach W, Gram LF, Rosholm JU, Mortensen PB, et al. 
Socio-economic inequalities in first-time use of antidepressants: a population-based 
study. Eur J Clin Pharmacol. 2004 Mar;60(1):51-5. 
 74 
14. Magrini N, Vaccheri A, Parma E, D'Alessandro R, Bottoni A, Occhionero M, et al. 
Use of benzodiazepines in the Italian general population: prevalence, pattern of use 
and risk factors for use. Eur J Clin Pharmacol. 1996;50(1-2):19-25. 
15. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia 
treatment: the use of benzodiazepines versus z-hypnotics. A prescription database 
study of predictors. Eur J Clin Pharmacol. 2009 Mar;65(3):295-301. 
16. Dening T, Barapatre C. Mental health and the ageing population. J Br Menopause Soc. 
2004 Jun;10(2):49-53, 64. 
17. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and 
behavioural disturbances and the use of psychotropic drugs in Norwegian nursing 
homes. Int J Geriatr Psychiatry. 2007 Sep;22(9):843-9. 
18. The Ministry of Health and Care Services. Regulation relating to a Municipal Regular 
GP Scheme.  Oslo2000; Available from: 
http://www.regjeringen.no/en/dep/hod/dok/lover_regler/reglement/2000/regulation-
relating-to-a-municipal-regul.html?id=420530. 
19. The Norwegian Labour and Welfare Service. Styringsdata for fastlegeordningen.  2008 
[cited 2011 06.06]; Available from: 
http://www.nav.no/Om+NAV/Tall+og+analyse/Annen+statistikk/Helsetjenester/Fastle
geordningen/_attachment/184202?=true&_ts=11f37d80d40. 
20. Grytten J, Skau I, Carlsen F. [Patient satisfaction with general practice services before 
and after the list patient reform]. Tidsskr Nor Laegeforen. 2004 Mar 4;124(5):652-4. 
21. Grytten J, Skau I, Sorensen R, Aasland OG. [Physicians' work situation a year after the 
list patient system reform]. Tidsskr Nor Laegeforen. 2004 Feb 5;124(3):358-61. 
22. Nossen JP. Hva foregår på legekontorene ? Konsultasjonsstatistikk for 2006 (What 
happens at the GPs' surgeries ? Consultation statistics for 2006). the Norwegian 
Labour and Welfare Services,; 2007 [cited 2011 25.08.]; Available from: 
http://www.google.com/#sclient=psy&hl=en&source=hp&q=Nossen+Hva+foreg%C3
%A5r+p%C3%A5+legekontorene&pbx=1&oq=Nossen+Hva+foreg%C3%A5r+p%C3
%A5+legekontorene&aq=f&aqi=&aql=&gs_sm=e&gs_upl=181l5769l1l6016l28l27l0l
0l0l0l253l4159l6.15.6l27l0&bav=on.2,or.r_gc.r_pw.&fp=183c70244841280&biw=12
80&bih=939. 
23. The Ministry of Health and Care Services. Stortingsmelding nr 25 (1996-97) ; Åpenhet 
og helhet – om psykiske lidelser og tjenestetilbudene. 1997. 
24. The Ministry of Health and Care Services. St.prp. nr. 63 (1997-1998) 
Opptrappingsplanen for psykisk helse 1999-2006. 1998. 
25. The Ministry of Finance. Report no. 1 (2009-2010), National Budget 2010 2009. p. 
291 - 324. 
26. Jacobsen E. The early history of psychotherapeutic drugs. Psychopharmacology (Berl). 
1986;89(2):138-44. 
27. Kuhn R. [Treatment of depressive states with an iminodibenzyl derivative (G 22355)]. 
Schweiz Med Wochenschr. 1957 Aug 31;87(35-36):1135-40. 
 75 
28. Shorter E. The history of lithium therapy. Bipolar Disord. 2009 Jun;11 Suppl 2:4-9. 
29. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, et al. 
Prescribing trends in psychotropic medications: primary care, psychiatry, and other 
medical specialties. JAMA. 1998 Feb 18;279(7):526-31. 
30. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of 
psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002 
May;41(5):514-21. 
31. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of 
pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010 Jan;121(1):4-10. 
32. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in 
older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-2; quiz 3-4. 
33. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the 
treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 
2000 Dec 2;321(7273):1371-6. 
34. Drug Consumption in Norway. The department of pharmacoepidemiology, Norwegian 
Institute of Public Health; 2009 [cited 2010 01-29]; Available from: 
http://www.legemiddelforbruk.no/english/. 
35. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch 
Gen Psychiatry. 2009 Aug;66(8):848-56. 
36. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise 
in antidepressant prescribing: a descriptive study using the general practice research 
database. BMJ. 2009;339:b3999. 
37. Zukov I, Ptacek R, Raboch J, Domluvilova D, Kuzelova H, Fischer S, et al. 
Premenstrual dysphoric disorder--review of actual findings about mental disorders 
related to menstrual cycle and possibilities of their therapy. Prague Med Rep. 
2010;111(1):12-24. 
38. Patten SB, Esposito E, Carter B. Reasons for antidepressant prescriptions in Canada. 
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):746-52. 
39. Taylor DJ, Roane BM. Treatment of insomnia in adults and children: a practice-
friendly review of research. J Clin Psychol. 2010 Nov;66(11):1137-47. 
40. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The 
efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis 
of RCTs. J Gen Intern Med. 2007 Sep;22(9):1335-50. 
41. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de 
Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst 
Rev. 2006;3:CD006115. 
42. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral 
toxicity of alprazolam: a review of the literature. CNS Drug Rev. 2004 
Spring;10(1):45-76. 
 76 
43. Who Collaborating Center for Drug Statistics Metodology. ATC / DDD Index 2010.  
2010; Available from: http://www.whocc.no/atc_ddd_index/. 
44. Who Collaborating Center for Drug Statistics Metodology.  2011; Available from: 
http://www.whocc.no/. 
45. The Norwegian Medicines Agency.  2011; Available from: 
http://www.legemiddelverket.no/templates/InterPage____16645.aspx?filterBy=CopyT
oGeneral. 
46. WHO International Working Group for Drug Statistics Methodology., WHO 
Collaborating Centre for Drug Statistics Methodology., WHO Collaborating Centre for 
Drug Utilization Research and Clinical Pharmacological Services. Introduction to drug 
utilization research. Geneva: World Health Organization; 2003. 
47. Strom BL, Kimmel SE. Textbook of pharmacoepidemiology. Chichester, West Sussex, 
England ; Hoboken, NJ: John Wiley & Sons; 2006. 
48. Saskatchewan Ministry of Health. Health Service Databases: Information document 
2010 [cited 2011 20.08.]; Available from: http://www.health.gov.sk.ca/health-
databases-info-doc. 
49. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research 
Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998 May;45(5):419-25. 
50. The General Practice Research Database. The General Practice Research Database.  
2011 [cited 2011 20.08.]; Available from: http://www.gprd.com/products/database.asp. 
51. The PHARMO Institute. The PHARMO Institute,;  [cited 2011 20.08. ]; Available 
from: http://www.pharmo.nl/. 
52. The InterAction database. The InterAction database.   [cited 2011 20.08.]; Available 
from: http://iadb.nl/index.php?id=1&language=en. 
53. Who Collaborating Center for International Drug Monitoring. VigiBase, the WHO 
Global ICSR Database system: Basic facts.  Uppsala, Sweden2007; Available from: 
http://www.who-umc.org/graphics/24965.pdf. 
54. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 
1997 Sep;44(4):445-8. 
55. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. 
The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin 
Pharmacol Toxicol. 2010 Feb;106(2):86-94. 
56. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – 
new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol. 
2008;18:129-36. 
57. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. 
Psychotropic drug utilization in Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 
2004(420):55-64. 
 77 
58. Nielsen MW, Hansen EH, Rasmussen NK. Patterns of psychotropic medicine use and 
related diseases across educational groups: national cross-sectional survey. Eur J Clin 
Pharmacol. 2004 May;60(3):199-204. 
59. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of 
France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. 2002 
Sep;63(9):817-25. 
60. Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic 
medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007 
May;16(5):560-70. 
61. Beck CA, Williams JV, Wang JL, Kassam A, El-Guebaly N, Currie SR, et al. 
Psychotropic medication use in Canada. Can J Psychiatry. 2005 Sep;50(10):605-13. 
62. Clavenna A, Rossi E, Derosa M, Bonati M. Use of psychotropic medications in Italian 
children and adolescents. Eur J Pediatr. 2007 Apr;166(4):339-47. 
63. Bonati M, Clavenna A. The epidemiology of psychotropic drug use in children and 
adolescents. int Rev Psychiatry. 2005 Jun;17(3):181-8. 
64. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, 
Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide 
population-based study. J Child Adolesc Psychopharmacol. 2009 Dec;19(6):757-64. 
65. Percudani M, Barbui C, Fortino I, Petrovich L. The prevalence of antidepressant and 
antipsychotic drug prescribing in Lombardy, Italy. J Clin Psychopharmacol. 2005 
Feb;25(1):92-4. 
66. Mortimer AM, Shepherd CJ, Rymer M, Burrows A. Primary care use of antipsychotic 
drugs: an audit and intervention study. Ann Gen Psychiatry. 2005 Nov 29;4:18. 
67. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? 
Psychiatr Serv. 2008 May;59(5):507-14. 
68. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general 
practitioners in the United Kingdom from 1991 to 2000: a population-based 
observational study. Br J Clin Pharmacol. 2003 Nov;56(5):569-75. 
69. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic 
prescribing pattern among Italian general practitioners: a population-based study 
during the years 1999-2002. Eur J Clin Pharmacol. 2005 Mar;61(1):47-53. 
70. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic 
prescribing to children and adolescents in primary care in the United Kingdom. 
Pediatrics. 2008 May;121(5):1002-9. 
71. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, et al. 
Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr 
Serv. 2008 May;59(5):554-60. 
72. Isacsson G, Boethius G, Henriksson S, Jones JK, Bergman U. Selective serotonin 
reuptake inhibitors have broadened the utilisation of antidepressant treatment in 
accordance with recommendations. Findings from a Swedish prescription database. J 
Affect Disord. 1999 Apr;53(1):15-22. 
 78 
73. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. 
Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol. 
2004 Mar;60(1):57-61. 
74. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in 
the outpatient treatment of depression. JAMA. 2002 Jan 9;287(2):203-9. 
75. Rosholm JU, Andersen M, Gram LF. Are there differences in the use of selective 
serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database 
study. Eur J Clin Pharmacol. 2001 Mar;56(12):923-9. 
76. Trifiro G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, et al. Antidepressant 
drugs: prevalence, incidence and indication of use in general practice of Southern Italy 
during the years 2003-2004. Pharmacoepidemiol Drug Saf. 2007 May;16(5):552-9. 
77. Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Ronning M. [Prescription of 
selective serotonin reuptake inhibitors 1990-2004]. Tidsskr Nor Laegeforen. 2005 Sep 
22;125(18):2470-3. 
78. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British 
Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv. 
2007 Jan;58(1):79-84. 
79. Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro N. Prescriptions 
of antidepressants in primary care in Italy: pattern of use after admission of selective 
serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol. 2004 
Jan;59(11):825-31. 
80. Exeter D, Robinson E, Wheeler A. Antidepressant dispensing trends in New Zealand 
between 2004 and 2007. Aust N Z J Psychiatry. 2009 Dec;43(12):1131-40. 
81. Zito JM, Tobi H, de Jong-van den Berg LT, Fegert JM, Safer DJ, Janhsen K, et al. 
Antidepressant prevalence for youths: a multi-national comparison. 
Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):793-8. 
82. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H, et al. 
Patterns and correlates of benzodiazepine use in the French general population. Eur J 
Clin Pharmacol. 2004 Sep;60(7):523-9. 
83. van Hulten R, Leufkens HG, Bakker A. Usage patterns of benzodiazepines in a Dutch 
community: a 10-year follow-up. Pharm World Sci. 1998 Apr;20(2):78-82. 
84. Isacson D. Long-term benzodiazepine use: factors of importance and the development 
of individual use patterns over time--a 13-year follow-up in a Swedish community. 
Soc Sci Med. 1997 Jun;44(12):1871-80. 
85. Boonstra G, Grobbee DE, Hak E, Kahn RS, Burger H. Initiation of antipsychotic 
treatment by general practitioners. a case-control study. J Eval Clin Pract. 2011 
Feb;17(1):12-7. 
86. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W. Antipsychotic prescribing 
patterns in Germany: a retrospective analysis using a large outpatient prescription 
database. Int Clin Psychopharmacol. 2003 Jul;18(4):237-42. 
 79 
87. McManus P, Mant A, Mitchell P, Britt H, Dudley J. Use of antidepressants by general 
practitioners and psychiatrists in Australia. Aust N Z J Psychiatry. 2003 
Apr;37(2):184-9. 
88. Tardieu S, Bottero A, Blin P, Bohbot M, Goni S, Gerard A, et al. Roles and practices 
of general practitioners and psychiatrists in management of depression in the 
community. BMC Fam Pract. 2006;7:5. 
89. Henriksson S, Isacsson G. Increased antidepressant use and fewer suicides in Jamtland 
county, Sweden, after a primary care educational programme on the treatment of 
depression. Acta Psychiatr Scand. 2006 Sep;114(3):159-67. 
90. Rihmer Z, Rutz W, Pihlgren H. Depression and suicide on Gotland. An intensive study 
of all suicides before and after a depression-training programme for general 
practitioners. J Affect Disord. 1995 Dec 18;35(4):147-52. 
91. Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric treatment in primary care 
patients with anxiety disorders: a comparison of care received from primary care 
providers and psychiatrists. Am J Psychiatry. 2007 Feb;164(2):276-82. 
92. Harpaz-Rotem I, Rosenheck RA. Prescribing practices of psychiatrists and primary 
care physicians caring for children with mental illness. Child Care Health Dev. 2006 
Mar;32(2):225-37. 
93. Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication 
consumption patterns in the UK general population. J Clin Epidemiol. 1998 
Mar;51(3):273-83. 
94. Percudani M, Barbui C, Fortino I, Petrovich L. Antidepressant drug use in Lombardy, 
Italy: a population-based study. J Affect Disord. 2004 Dec;83(2-3):169-75. 
95. Verdoux H, Gaudron Y, Tournier M. Transition in care in persons with antidepressant 
prescription in naturalistic conditions. Fam Pract. 2011 Mar 11. 
96. Henriksson S, Boethius G, Hakansson J, Isacsson G. Indications for and outcome of 
antidepressant medication in a general population: a prescription database and medical 
record study, in Jamtland county, Sweden, 1995. Acta Psychiatr Scand. 2003 
Dec;108(6):427-31. 
97. The Norwegian Institute of Public Health. The Norwegian Prescription Database 2009; 
Available from: http://www.norpd.no/. 
98. St.meld. nr. 18 (2004-2005) Rett kurs mot riktigere legemiddelbruk. In: Services 
TMoHaC, editor.2005. 
99. The Norwegian Prescription Database. The Norwegian Institute of Public Health;  
[cited 2011 20.08.]; Available from: http://www.norpd.no/. 
100. Richard Lowry. VassarStats: Website for Statistical Computation.  2011; Available 
from: http://faculty.vassar.edu/lowry/VassarStats.html. 
101. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe--a critical 
review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005 Aug;15(4):357-
76. 
 80 
102. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size 
and burden of mental disorders and other disorders of the brain in Europe 2010. Eur 
Neuropsychopharmacol. 2011 Sep;21(9):655-79. 
103. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull 
World Health Organ. 2004 Nov;82(11):858-66. 
104. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their 
long-term use and alternative agents. J Clin Psychiatry. 2005;66 Suppl 2:21-7. 
105. Kringlen E, Torgersen S, Cramer V. A Norwegian psychiatric epidemiological study. 
Am J Psychiatry. 2001 Jul;158(7):1091-8. 
106. Kringlen E, Torgersen S, Cramer V. Mental illness in a rural area: a Norwegian 
psychiatric epidemiological study. Soc Psychiatry Psychiatr Epidemiol. 2006 
Sep;41(9):713-9. 
107. Menary KR, Kushner MG, Maurer E, Thuras P. The prevalence and clinical 
implications of self-medication among individuals with anxiety disorders. J Anxiety 
Disord. 2011 Apr;25(3):335-9. 
108. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-
14. 
109. Carrigan MH, Randall CL. Self-medication in social phobia: a review of the alcohol 
literature. Addict Behav. 2003 Mar;28(2):269-84. 
110. Statistics Norway. StatBank Norway.  2010; Available from: 
http://statbank.ssb.no//statistikkbanken/default_fr.asp?PLanguage=1. 
111. Kirkevold O, Engedal K. Is covert medication in Norwegian nursing homes still a 
problem? A cross-sectional study. Drugs Aging. 2009;26(4):333-44. 
112. Mannesse CK, Derkx FH, de Ridder MA, Man in 't Veld AJ, van der Cammen TJ. 
Contribution of adverse drug reactions to hospital admission of older patients. Age 
Ageing. 2000 Jan;29(1):35-9. 
113. Zopf Y, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG, et al. Women 
encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008 Oct;64(10):999-
1004. 
114. Hartholt KA, van der Velde N, Looman CW, Panneman MJ, van Beeck EF, Patka P, et 
al. Adverse drug reactions related hospital admissions in persons aged 60 years and 
over, The Netherlands, 1981-2007: less rapid increase, different drugs. PLoS One. 
2010;5(11):e13977. 
115. Cohen-Mansfield J, Libin A. Verbal and physical non-aggressive agitated behaviors in 
elderly persons with dementia: robustness of syndromes. J Psychiatr Res. 2005 
May;39(3):325-32. 
116. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of 
aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 
2006(1):CD003476. 
 81 
117. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment 
of behavioral and psychological symptoms in dementia, with a particular focus on 
longer term outcomes and mortality. Expert Opin Drug Saf. 2011 Jan;10(1):35-43. 
118. Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele 
RH. Systematic appraisal of dementia guidelines for the management of behavioural 
and psychological symptoms. Ageing Res Rev. 2011 Aug 10. 
119. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to 
reduce behavioural disturbances in residents of nursing homes with dementia: cluster 
randomised clinical trial. BMJ. 2011;343:d4065. 
120. Wilkins VM, Kiosses D, Ravdin LD. Late-life depression with comorbid cognitive 
impairment and disability: nonpharmacological interventions. Clin Interv Aging. 
2010;5:323-31. 
121. Hansen DG, Rosholm JU, Gichangi A, Vach W. Increased use of antidepressants at 
the end of life: population-based study among people aged 65 years and above. Age 
Ageing. 2007 Jul;36(4):449-54. 
122. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. 
Antidepressant use and risk of adverse outcomes in older people: population based 
cohort study. BMJ. 2011;343:d4551. 
123. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. 
Drugs Aging. 2009;26(5):381-94. 
124. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug 
interactions, dosage, and duration of therapy on the risk of hip fracture associated with 
benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010 
Dec;19(12):1248-55. 
125. van Hulten R, Isacson D, Bakker A, Leufkens HG. Comparing patterns of long-term 
benzodiazepine use between a Dutch and a Swedish community. Pharmacoepidemiol 
Drug Saf. 2003 Jan-Feb;12(1):49-53. 
126. van Hulten R, Teeuw KB, Bakker A, Leufkens HG. Initial 3-month usage 
characteristics predict long-term use of benzodiazepines: an 8-year follow-up. Eur J 
Clin Pharmacol. 2003 Feb;58(10):689-94. 
127. Neutel CI. The epidemiology of long-term benzodiazepine use. int Rev Psychiatry. 
2005 Jun;17(3):189-97. 
128. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. World 
Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the 
pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress 
disorders - first revision. World J Biol Psychiatry. 2008;9(4):248-312. 
129. World Health Organization. Pharmacological treatment of mental disorders in primary 
health care.  Geneva2009; xi, 69 p.]. Available from: 
http://whqlibdoc.who.int/publications/2009/9789241547697_eng.pdf. 
 
 82 
130. Norwegian Board of Health Supervision. Vanedannende legemidler, forskrivning og 
forsvarlighet.  2001; Available from: 
http://www.helsetilsynet.no/upload/Publikasjoner/andrepublikasjoner/vanedannende_l
egemidler_forskrivning_forsvarlighet_ik-2755.pdf. 
131. Norwegian Medicines Agency. Behandling av søvnvansker.  2000; Available from: 
http://www.legemiddelverket.no/upload/76527/publikasjon8-2000.pdf. 
132. Veronese A, Garatti M, Cipriani A, Barbui C. Benzodiazepine use in the real world of 
psychiatric practice: low-dose, long-term drug taking and low rates of treatment 
discontinuation. Eur J Clin Pharmacol. 2007 Sep;63(9):867-73. 
133. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are 
they justified? Eur Neuropsychopharmacol. 1999 Dec;9 Suppl 6:S399-405. 
134. Halvorsen KH, Granas AG, Engeland A, Ruths S. Prescribing quality for older people 
in Norwegian nursing homes and home nursing services using multidose dispensed 
drugs. Pharmacoepidemiol Drug Saf. 2011 Sep 13. 
135. The National Board of Health and Welfare. Läkemedelsregistret.  2011; Available 
from: http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret. 
136. The Ministry of Health and Care Services. The Coordination Reform.  2009; Available 
from: http://www.regjeringen.no/upload/HOD/Samhandling%20engelsk_PDFS.pdf. 
137. Murrihy R, Byrne MK. Training models for psychiatry in primary care: a new frontier. 
Australas Psychiatry. 2005 Sep;13(3):296-301. 
138. Blashki G, Selzer R, Judd F, Hodgins G, Ciechomski L. Primary care psychiatry: 
taking consultation-liaison psychiatry to the community. Australas Psychiatry. 2005 
Sep;13(3):302-6. 
139. Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindbaek M. Can antibiotic 
prescriptions in respiratory tract infections be improved? A cluster-randomized 
educational intervention in general practice--the Prescription Peer Academic Detailing 
(Rx-PAD) Study [NCT00272155]. BMC Health Serv Res. 2006;6:75. 
140. Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized 
educational intervention to reduce inappropriate prescription patterns for elderly 
patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) 
study [NCT00281450]. BMC Health Serv Res. 2006;6:72. 
 
 
